Purinergic system: regulations and interactions by Tonazzini, Ilaria
  
UNIVERSITÀ DI PISA 
 
 
Scuola di Dottorato di Ricerca in  
“Scienza del Farmaco e delle Sostanze Bioattive” 
 
 
Dottorato di Ricerca in 
“Scienza del Farmaco e delle Sostanze Bioattive” 
XIX CICLO (2004-2006) 
 
 
 
 
 
 
“ Purinergic system: regulations and interactions ” 
 
 
 
 
 
 
 
 
 
 
 
 
 
CANDIDATO:         TUTOR: 
    Dott. Ilaria Tonazzini       Prof. Claudia Martini 
           
 
 
 
 
DIRETTORE DELLA SCUOLA 
(Prof.ssa Claudia Martini) 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“ All truths are easy to understand once they are discovered; 
the point is to discover them ” 
 
Galileo Galilei 
  
INDEX 
 
 
Chapter 1: Introduction 
 
1.1 Purinergic system       pag.   1 
1.2 Adenosine and adenosine receptors     pag.   4 
1.3 ATP and purinergic receptors     pag.   6 
1.4 Astroglial cells       pag. 10 
1.5 Aim of the work: 
1.5.1 A1-P2Y1 receptors      pag. 11 
1.5.2 A2B receptors       pag. 13 
1.6 References        pag. 15 
 
 
Chapter 2: Co-localization and functional cross-talk between A1 and P2Y1 
purine receptors in rat hippocampus 
 
2.1 Abstract        p. 22 
2.2 Introduction        p. 23 
2.3 Materials and methods 
2.3.1 Materials       p. 24 
2.3.2 Postembedding Immunogold Cytochemistry   p. 25 
2.3.4 Immunocytochemistry Quantitative Analysis  p. 27 
2.3.5 Rat brain membrane lysates and Western blotting  p. 29 
2.3.6 Rat hippocampal membrane preparation for [35S]GTPγS 
binding assay       p. 30 
2.3.7 [35S]GTPγS binding assay on rat hippocampal membranes p. 30 
2.3.8 Data analysis        p. 31 
2.4 Results 
2.4.1 Immunolocalization      p. 31 
2.4.2 Functional assays      p. 45 
2.5 Discussion 
  
2.5.1 Immunolocalization and co-localization   p. 48 
2.5.2 Functional interaction     p. 49 
2.6 References        p. 53 
 
 
Chapter 3: Functional cross-talk between A1 and P2Y1 purine receptors in 
human astroglial cells 
 
3.1 Introduction        p. 61 
3.2 Materials and methods 
3.2.1 Materials       p. 63 
3.2.2 Cell culture       p. 64 
3.2.3 Cell treatments      p. 64 
3.2.4 Lysates, immunoprecipitates and western blotting   p. 65 
3.2.5 ADF membrane preparation for [35S]GTPγS and  
[3H]DPCPX binding assays     p.66 
3.2.6 [3H]DPCPX binding assay     p. 66 
3.2.7 [35S]GTPγS binding assay on ADF cell membranes  p. 67 
3.2.8 cAMP assay on ADF cells     p. 67 
3.2.9 Data analysis       p. 68 
3.3 Results 
3.3.1 Immunoprecipitation and Western-blotting   p. 68 
3.3.2 [3H]DPCPX binding assay     p. 70 
3.3.3 [35S]GTPγS binding assay     p. 72 
3.3.4 cAMP Assay       p. 77 
3.4 Discussion        p. 82 
3.5 References        p. 84 
 
 
Chapter 4: Short-term TNF-alpha treatment induced A2B adenosine receptor 
desensitization in human astroglial cells 
 
4.1 Abstract        p. 90 
  
4.2 Introduction        p. 90 
4.3 Materials and methods 
4.3.1 Materials       p. 92 
4.3.2 Cell culture and treatments     p. 92 
4.3.3 [35S]GTPγS Binding Assay on ADF cell membranes p. 93 
4.3.4 cAMP Assay on ADF cells     p. 93 
4.3.5 A2BR Immunoprecipitation and Immunoblotting  p. 94 
4.3.6    Data analysis      p. 95 
4.4 Results 
4.4.1 A2BR-G protein coupling in control and short-term  
TNF-alpha treated cells     p. 95 
4.4.2 A2BR functional responsiveness in control and short-term 
TNF-alpha treated cells     p. 98 
4.4.3 A2BR expression and phosphorylation levels in control and  
short-term TNF-alpha treated cells    p. 101 
4.4.4 A2B AR-mediated ERK ½ phosphorylation in control and  
short-term TNF-alpha treated cells    p. 104 
4.5 Discussion        p. 106 
4.6 References        p. 109 
 
 
Chapter 5: General conclusions and perspectives 
 
5.1 Conclusions 
5.1.1 A1R-P2Y1R       p. 114 
5.1.2 A2BR-cytokine       p. 115 
5.2 Future perspectives       p. 116 
5.3 References        p. 117 
 
 
  
Abbreviations 
 
A1R, A1 adenosine receptor; 
A2BR, A2B adenosine receptor; 
ADA, adenosine deaminase;  
ADF, human astrocytoma cells;  
ADP, adenosine 5’-diphosphate;  
ARs, adenosine receptors;  
ATP, adenosine 5’-triphosphate;  
CA1 & CA3, cornu ammonis 1 & 3 (hippocampal subfields); 
cAMP, cyclic adenosine 5’-monophosphate; 
CGS 21680, 2-(carboxyethylphenylethylamino)adenosine-5’-carboxamide;  
CHA, N6-cyclohexyladenosine;  
CNS, Central Nervous System;  
DPCPX, 8-cyclopentyl-1,3 dipropyl xanthine;  
FSK, forskolin;  
GDP, guanosine 5’-diphosphate;  
GPCR, G protein-coupled receptor;  
GTP, guanosine 5’-triphosphate;  
GTPγS, guanosine-5'-(γ-thio)triphosphate;  
HC, hippocampal membranes; 
MeSADP, 2-methylthio-adenosine 5’-diphosphate;  
MRS 1220, 9-chloro-2-(2-furyl)-5-phenylacetamino[1,2,4]triazolo[1,5-c]quinazoline;  
MRS 1706, N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-
purin8-phenoxyl]acetamide;  
MRS2179, 2’-deoxy-N6-methyl adenosine 3’,5’-diphosphate;  
NECA, 5’-N-ethylcarboxamidoadenosine;  
P2Y1R, purinergic P2Y1 receptor; 
PSD, postsynaptic density; 
PTX, Pertussis-toxin; 
R-PIA, (-)-N6-(2-Phenylisopropyl)-adenosine;  
 
 
  
SCH 58261, 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3e]-1,2,4-
triazolo[1,5c]pyrimidine; 
TNF-α or TNF-alpha, tumor necrosis factor-alpha. 
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Chapter 1: 
Introduction 
 
 
 
1.1 Purinergic system 
Purines have major roles in the activities of non-neuronal cells as well as neurons. This 
includes fast signalling roles in exocrine and endocrine secretion, platelet aggregation, 
vascular endothelial cell-mediated vasodilation and nociceptive mechano-sensory trans-
duction, as well as acting as a co-transmitter and neuromodulator in most, if not all, 
nerve types in the peripheral and central nervous systems. More recently, slow (trophic) 
purinergic signalling has been implicated in cell proliferation, migration, differentiation 
and death in embryological development, wound healing, restenosis, atherosclerosis, 
ischemia, cell turnover of epithelial cells in skin and visceral organs, inflammation, neu-
roprotection and cancer (Burnostock, 2006). 
In the late 1960s the search for the transmitter responsible for the non-adrenergic and 
non-cholinergic nerve responses led to the surprising proposal that ATP or a related nu-
cleotide might be the transmitter involved in both the gut and the bladder (Burnstock et 
al., 1972). This “purinergic hypothesis” met considerable resistance for the next 20 
years, partly perhaps because ATP was recognized at that time as an intracellular mole-
cule contained in all cells and of particular importance as an energy source, and it was 
considered that such a ubiquitous molecule was unlikely to act as a neurotransmitter, 
even though the presence of powerful ecto-enzymes for the breakdown of ATP was al-
ready known. 
Later co-transmission turned out to be the rule, rather than the exception, and in fact the 
significance of purinergic transmission was much extended by this concept. Evidence 
for ATP as a co-transmitter, even if with variable levels of contribution, has been found 
for all peripheral or central nerves so far investigated (Burnstock, 2004). 
Purinergic receptors were first defined in the late 1970s and a basis for distinguishing 
two types of purinoceptors, named P1 and P2 for adenosine and ATP/ADP, respec-
tively, was proposed (Burnstock, 1978).  
  
In the early 1990s, receptors for purines were cloned: four P1 receptor subtypes and 
seven P2X ionotropic and eight P2Y metabotropic receptor subtypes are currently rec-
ognized and characterized. 
P1 and P2Y purinergic receptors belong to the family of G protein coupled receptors 
(GPCRs), the largest family of cell-surface molecules involved in signal transmission, 
activated by a wide variety of ligands, including peptide and non-peptide neurotransmit-
ters, hormones, growth factors, odorant molecules and light. The large number of 
GPCRs and the importance of their physiological roles have made the search for novel 
therapeutic drugs an important and constantly expanding activity in the pharmaceutical 
industry: indeed these receptors are the target of more than 50% of the current therapeu-
tic agents on the market (Marinissen and Gutkind, 2001). 
These receptors share a seven trans-membrane helixes common structure, connected by 
three extracellular and three intracellular loops and constituted by an extracellular 
amino terminus and an intracellular carboxyl tail. Activated receptors interact with het-
erotrimeric G proteins that, through their α and βγ subunits, modulate the activity of 
membrane effectors such as enzymes (adenylyl and guanylyl cyclases, phosphodi-
esterases, phospholipases) or ionic channels. These membrane effectors generate second 
messengers (such as cAMP, diacylglycerol or inositol trisphosphate) and/or alter the in-
tracellular concentration of critical ions (such as Ca2+, Na+, K+), which trigger phos-
phorylation-dephosphorylation cascades that propagate the signal intracellularly to pro-
duce the final actions (Fig. 1). It has been recently shown that most biological responses 
mediated by GPCRs are not dependent on a single biochemical route, but result from 
the integration of the functional activity of an intricate network of intracellular signal-
ling pathways. Furthermore G protein-coupled receptors are dynamically regulated, fre-
quently through phosphorylation-dephosphorylation cycles (Vazquez-Prado et al., 
2003). 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 1: Diversity of G-protein-coupled receptors (GPCRs). A wide vari-
ety of ligands, including purine, use GPCRs to stimulate cytoplasmic and 
nuclear targets through heterotrimeric G-protein-dependent and -
independent pathways. Such signaling pathways regulate key biological 
functions such as cell proliferation, cell survival and angiogenesis. Ab-
breviations: DAG, diacylglycerol; GEF, guanine nucleotide exchange 
factor; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; PLC, 
phospholipase C. Modified from Marinissen and Gutkind (2001). 
 
 
  
1.2 Adenosine and adenosine receptors 
The purine nucleoside adenosine plays a central role in the energy metabolism of any 
cell and its formation, by breakdown of ATP in the extracellular space, is closely related 
to the energy consumption of the cell: in fact its concentration, although strictly regu-
lated by deamination or phosphorylation metabolism, can increase dramatically when 
there is an imbalance between energy use and energy supply (Fredholm, 1997). It is 
recognized as a very important substance in the homeostasis of CNS cells; due to the 
complex regulation of energy metabolism and adenosine levels, the extracellular adeno-
sine concentration in all body fluids is rather constant under basal conditions (30-300 
nM), but oxygen depletion induces a rise in extracellular adenosine to 10 µM or even 
higher (Schulte and Fredholm, 2003).  
Under basal conditions and in particular in emergency situations, adenosine plays a ma-
jor role in the central nervous system, in the cardiovascular system, as an endogenous 
pain modulator, the immune system, mast cell degranulation, asthma, cell growth, pro-
liferation and apoptosis (for review Fredholm et al., 2001 and 2005). 
The purine nucleoside adenosine acts on a family of GPCRs, collectively called adeno-
sine receptors (AR) or P1 purinoceptors: four distinct adenosine receptor subtypes, A1, 
A2A, A2B and A3, have been cloned and biochemically-pharmacologically characterized 
(Fredholm, 1995; Fredholm et al., 2001).  
They are coupled to an intricate network of signalling pathways involving classical sec-
ond messenger pathways, such as modulation of cAMP production or the phospholipase 
C (PLC) pathway, and in addition interact with mitogen-activated protein kinases 
(MAPK), which could give them a role in cell growth, survival, death and differentia-
tion.  
The original classification of adenosine receptors was based on their effects on cAMP 
levels in different tissues: A1 and A3 adenosine receptors mediate a decrease in cAMP 
via Gi/o, whereas the two A2 receptors, the high-affinity A2A and low-affinity A2B sub-
types, mediate an increase in cAMP via Gs (Schulte and Fredholm, 2003).  
In particular: 
 
• The A1 adenosine receptor (A1R), highly affine for adenosine, acts through in-
hibition of adenylyl cyclase, activation of several type of K+ channels, inactiva-
tion of N, P and Q-type Ca+2 channels, activation of phospholipase C and acti-
  
vation of ERK ½. A1Rs mediate inhibitory actions both presynaptically, by re-
ducing transmitter release, and postsynaptically, by hyperpolarizing neurons 
(but also astrocytes): A1Rs protect in this manner CNS cells from the excitotox-
icity present during pathophysiological states (Haas and Selbach, 2000). In fact, 
lines of evidence for an A1R neuroprotective role have been extensively sup-
plied by both in vitro and in vivo studies (reviewed by Schubert et al., 1997; 
Ribeiro et al., 2003).  
 
• The A2B adenosine receptor (A2BR), named “low affinity” receptor (Beukers et 
al., 2000), generally couples to Gs, but several studies implicated signalling via 
Gq/11. Little is known about the cell-specific expression of the A2BR in vivo or 
about their functional significance, also because there is a lack of specific ago-
nists for this receptor. Despite this limitation, the A2BR has been implicated in 
several important biological events, such as mediating vasodilation, inhibiting 
growth of rat aortic smooth muscle cells and controlling the production of cyto-
kines and inflammation (reviewed by Feoktistov et al., 1998; Yang et al., 
2006). 
 
Moreover in the CNS, adenosine is a “fine-tuner neuromodulator” (Ribeiro et al., 2002) 
and, as a central substance in energy metabolism, can effectively regulate neuronal fir-
ing and communication: in general, it has an inhibitory activity, mainly mediated by 
A1Rs, correlated with low energy reserve. Increasing demand and decreasing availabil-
ity of energy as they occur during excessive neuronal activity, hypoxia or hypoglycemia 
are associated with high adenosine levels that provide a protective feedback in such 
pathological situations (Haas and Selbach, 2000).  
Although adenosine is not a neurotransmitter on its own, it shares many properties, via 
A1R activation, with inhibitory neurotransmitters (i.e. GABA), such as the control of 
glutamatergic transmission in CNS; nevertheless adenosine might indirectly control 
GABAergic functioning (Ribeiro et al., 2003). Excitatory actions, on the other hand, are 
mediated by ATP and high levels of intracellular ATP provide for high neuronal excit-
ability when ATP-sensitive K+ channels are closed (Haas and Selbach, 2000). 
  
1.3 ATP and purinergic receptors 
Extracellular adenosine 5’-triphosphate (ATP) has been recognized as a ubiquitous sig-
nalling molecule, acting as a fast neurotransmitter and modulator of transmitter release 
and neuronal excitability and participating in cell differentiation, proliferation and sur-
vival, as well as a toxic agent that mediates cellular degeneration and death (Burnstock, 
2006). There is a large gradient for ATP transport or secretion out of cells; this happens 
via ATP transporters, channels or via Ca2+-mediated exocytosis from synaptic vesicles, 
together with classical neurotrasmitters. Intracellular ATP concentrations are in the mil-
limolar range, whereas extracellular ATP concentrations rely on the balance between 
release and degradation (the concentration estimates range from nanomolar to micromo-
lar) (reviewed by Franke and Illes, 2006). A dramatic release of ATP and purines occurs 
after cellular death, via the damaged cell membranes.  
Ecto-nucleotidase family enzymes limit the extracellular actions of ATP by enhancing 
its removal as well as by producing adenosine, which can functionally antagonize some 
effects of ATP. In neuronal tissue, AMP, ADP, and ATP were shown to be rapidly con-
verted to adenosine with a t1/2 of 200 msec (Zimmermann, 2000).  
Potential sources of extracellular purines in the CNS include neurons, glia, endothelium 
and blood. Purinergic mechanisms may be involved in the ethiopathology of many neu-
rodegenerative conditions, especially because massive extracellular release of ATP, 
adenosine and other neurotransmitters occurs. During different kinds of “acute” (i.e. 
ischemia, hypoxia, mechanical stress) and ”chronic” pathological conditions (i.e. pain, 
epilepsy, drug exposure, retinal diseases, Alzheimer’s disease and possibly Parkinson’s 
disease), purinergic receptor activation could either be a cause or a consequence of neu-
ronal cell death/glial activation and may be related to detrimental and/or beneficial ef-
fects (reviewed by Franke and Illes, 2006). 
In 1972, Burnstock proposed the concept of ATP as a neurotransmitter (Burnstock, 
1972); subsequently the existence of special cellular sites of action for nucleotides as P2 
purino-receptors was published in 1978 (Burnstock, 1978). 
There are two principal families of P2 receptors (Abbracchio and Burnstock, 1994), 
widely expressed in the CNS:  
 
 
 
  
• P2X receptors (P2XR), which are ligand-gated ion channels; 
• P2Y receptors (P2YR), which belong to the group of GPCRs. 
 
P2Rs are expressed on the surface of almost all cells. Up to now 7 mammalian P2XR 
subtypes (P2X1-7) and 8 mammalian P2YR subtypes (P2Y1,2,4,6,11,12,13,14) have been 
cloned and functionally defined as P2Rs (Ralevic and Burnstock, 1998; Abbracchio et 
al., 2003) (Fig. 2). As recommended by the IUPHAR nomenclature committee, the term 
“P2Y” will be used for cloned GPCRs that have been shown to mediate effects of ex-
tracellular nucleotides (Fredholm et al., 1997).  
 
 
 
Fig. 2: Schematic diagram illustrating ATP actions at synapses: pho-
spholipase A2 (PLA2), phospholipase D (PLD), protein kinase C (PKC), 
adenylate cyclase (AC), phospholipase C (PLC), diacylglycerol (DAG), 
inositol-(1,4,5)-trisphosphate (IP3), nitric oxide synthase (NOS), pho-
sphoinositide 3-kinase (PI3K), serine-threonine kinase (AKT), mitogen-
activated protein kinase (MAPK), extracellular signal-regulated kinases 
1 and 2 (ERK1/2), c-Jun N-terminal kinases (JNKs), cyclic guanosine 
monophosphate (cGMP), arachidonic acid (AA), cyclooxygenase 
(COX), nitric oxide (NO) and nuclear factor kappa B (NFnB). 
 
 
 
  
All known P2YRs possess at their extracellular domains 4 cysteine residues, which are 
likely to form two disulfide bridges (Hoffmann et al., 1999). The receptors of a first 
group (P2Y1-2-4-6-11 R), all couple via Gq proteins to stimulation of phospholipase C fol-
lowed by increases in inositol phosphates and mobilization of Ca2+ from intracellular 
stores. The receptors of a second group (P2Y12-13-14 R) all couple via Gi proteins to inhi-
bition of adenylate cyclase, followed by a decrease in intracellular cAMP levels (Von 
Kugelgen, 2006).  
Members of this P2 receptor family are widely expressed in the CNS and are involved 
in glia-glia and glia-neuron communications, whereby they play important physiologi-
cal and patho-physiological roles in a variety of biological processes. 
In particular, the P2Y1R, first cloned from late-embryonic chick brain (Webb et al., 
1993) and then detected in other mammalian species, is selective for adenine nucleo-
tides, principally activated by ADP nucleotides. The agonist compound MeSADP has a 
10 times higher affinity at the human P2Y1R than ADP; however, ATP itself is a partial 
agonist with a reduced intrinsic activity when compared with that of ADP (Waldo and 
Harden, 2004). There are P2Y1R subtype-selective antagonists available, such as the 
MRS2179 (Camaioni et al., 1998): the affinity constant of MRS2179 at the human 
P2Y1R amounts to about 100 nM (Waldo et al., 2002) and it doesn’t change responses 
mediated by other P2YRs (Von Kugelgen, 2006). 
P2Y1Rs: mediate muscle relaxation and the release of endothelium-derived relaxing fac-
tors or prostaglandins, thus contributing to the ADP-induced platelet aggregation (Fabre 
et al., 1999); result localized at characteristic Alzheimer’s disease structures in the hip-
pocampus and cortex (Moore et al., 2000); are involved in apoptotic events (Sellers et 
al., 2001; Mamedova et al., 2006) as well in the gliotic response under physiological 
and pathological conditions (Franke et al., 2001; 2004). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Table 1: The table summarizes cloned mammalian P2YRs that have 
been proved to mediate actions of extracellular nucleotides when ex-
pressed and studied in functional assay systems (Access No: GenBank 
accession No; Chr. l: chromosomal location). Table modified from Von 
Kugelgen (2006). 
  
1.4 Astroglia 
Astroglial cells are the most abundant cells in the CNS and it appears that the ratio of 
astrocytes to neurons increases with the increasing complexity of the CNS (Pekny and 
Pekna, 2004). In fact in the CNS astroglia is involved in multiple brain functions under 
physiological conditions, including neuronal development, synaptic activity and homeo-
static control of the extracellular environment (Ciccarelli et al. 2001; Anderson et al., 
2003). In particular, astrocytes (Fig. 3) are involved in the most integrated functions of 
the CNS: on one hand they may contribute to damage by propagating spreading depres-
sion or by sending pro-apoptotic signals to healthy tissue via gap junction channels or 
by inhibiting regeneration by formation of the glial scar; on the other hand, astrocytes 
are important in neuronal antioxidant defence, secrete growth factors, promote neuro-
genesis and regeneration in the chronic phase after injury (Anderson et al., 2003).  
 
 
 
 
Astrocytes actively participate in the processes triggered by brain injury, which are ini-
tially aimed at limiting and repairing brain damage but may eventually contribute to 
neuronal cell death. Under pathological conditions, such as hypoxia or ischemia, they in 
fact turn into an activated form called “reactive astrogliosis” (Brambilla and Abbracchio 
  
2001; Brambilla et al. 2003). Although it is accepted that activated astrocytes contribute 
to isolate damaged brain areas from surrounding healthy cells and participate in neu-
ronal recovery synthesizing neurotrophins and pleiotrophins, these cells also release 
several potentially toxic compounds (i.e. nitric oxide and cytokines; Neary et al., 1996) 
and an excessive and prolonged astrogliosis, such as that found in acute and chronic 
neurodegenerative diseases, may contribute to brain damage. In addition, astrocytes ex-
ert an important role in the modulation of extracellular glutamate, which is the main ex-
citatory neurotransmitter within the CNS, in pathological conditions characterized by 
neurotoxic glutamate accumulation, such as cerebral ischemia and traumatic brain in-
jury.  
Nevertheless glia has been found to be more vulnerable to apoptosis than neurons in fo-
cal ischemic infarction (Petito et al., 1998). 
Astrocytes, which play a critical role in brain homeostasis in that they control the local 
environment in normal as well as in pathological conditions, have recently been identi-
fied as a source for a wide variety of glio-trasmitters that modulate synaptic activity 
(Martin et al., 2007). 
Growing evidence indicates that purines are widely involved in the molecular mecha-
nisms underlying the multiple functions of astrocytes, either by exerting their influence 
on key intracellular activities (energy metabolism, nucleic acid synthesis) or activating 
their membrane receptors (Neary et al., 1996; Abbracchio and Burnstock 1998). 
 
 
1.5 Aim of the work 
 
1.5.1 A1-P2Y1 receptors 
In support of the assumption that cerebral ischemia or mechanical damages aggravate 
brain injury via the efflux of ATP, evidence suggests that the interference with the 
purinergic system (in particular the ATP excitatory system) could provide neuroprotec-
tion, thus improving functional recovery and diminishing cell death in the peri-
traumatic zone (Franke and Illes, 2006). Anyhow detailed investigations on the sys-
temic application of these compounds, either to animals or human volunteers/patients, 
are still missing.  
  
Whereas the neuroprotective role of adenosine analogues active at the A1R subtype has 
been known for several years, the function of P2Y1 rceptor has not been fully character-
ized, enough if its broad distribution in a variety of cell-types throughout the brain of 
different species (Zhu et al., 2001; Moran-Jimenez and Matute, 2000; Webb et al., 
1998) indicates important physiological and patho-physiological functions; indeed, 
changes in the expression of P2Y1Rs are reported in different cell types and tissues, as 
consequence of a wide range of pathological conditions (Moore et al, 2000; Neary et al., 
2003; Lammer et al., 2004; Franke et al., 2004; Luttikhuizen et al., 2004).  
The synthesis of P2Y1R antagonistic compounds, permeable through the blood-brain 
barrier, has been proposed with a therapeutic potential, for example, by decreasing the 
excessive glutamate release in the CNS or by reducing the size of the glial scar follow-
ing ischemic attacks (Franke and Illes, 2006). Anyway in the same time ATP, but no 
adenosine, showed to protect astrocytes against the cell death induced by oxidative 
stress damage, via P2Y1R activation (Shinozaki et al., 2005). 
It is now well ascertained that GPCRs can be directly associated as either mono- or het-
ero-oligomers, thus altering their functions (Maggio et al., 2005) during physio-
pathological conditions; the activation of one particular signalling pathway of a GPCR 
can either amplify or inhibit the intracellular pathway of another. 
A1 receptors have shown to act synergistically with P2Y receptors and, in particular, 
with P2Y1Rs (Masino et al., 2002; Fredholm et al., 2003). Recently it has been demon-
strated that A1Rs can form a heteromeric complex with P2Y1Rs (Yoshioka et al., 2001; 
2002): heterodimerization between A1 and P2Y1 receptors thus generates an adenosine 
receptor which has a P2Y-like receptor agonistic pharmacology and acts also through 
adenylyl cyclase signalling pathway. 
So, considering the relevance of the A1R-, P2Y1R- and astroglia-mediated actions in the 
CNS, the aim of this work has been: 
 
• As a first step, to investigate the subcellular/cellular localization/co-localization 
of A1Rs and P2Y1Rs in hippocampus, a particularly damage-sensitive area, fo-
cusing in particular on the glutamatergic synapses and surrounding areas, and 
their functional cross-talk at membrane levels, in crude hippocampal mem-
branes; 
  
• As a second step, to investigate the A1R-P2Y1R cross-talk in human astroglial 
cells, in particular the functional implications of P2Y1R activation on A1R func-
tioning. 
 
 
1.5.2 A2B receptors 
Adenosine has been identified as a significant paracrine inhibitor of inflammation (Lin-
den, 2005), but it has not been certain which of its receptors mediate this effect. There is 
growing interest in elucidating the mechanisms by which adenosine inhibits the in-
flammation, since the adenosine receptors are promising targets for new anti inflamma-
tory therapies.  
Recently A2BR has been identified as a critical regulator of inflammation. After a num-
ber of previous reports indicating that A2BR activation can be pro-inflammatory (Lin-
den, 2006), a recent work (Yang et al., 2006) reports a pro-inflammatory phenotype re-
sulting from deletion of the gene encoding the A2BR in mice and suggests that activation 
of A2BRs can also have anti-inflammatory effects, as already reported in macrophages 
(Xaus et al., 1999; Kreckler et al., 2006). In line with this, Rosi and co-workers (2003) 
found that LPS-mediated chronic brain inflammation was associated with microglia ac-
tivation and neuronal A2BR down-regulation. Nevertheless, an up-regulation of A2BRs, 
in hippocampal astrocytes, mediated an important role in the protective effects of cere-
bral ischemic preconditioning in rats (Zhou et al., 2004). At the present the role of the 
A2BR remains enigmatic since its activation can either stimulate or inhibit the release of 
proinflammatory cytokines, in different cells and tissues. Nevertheless the effects of 
adenosine on astrocyte functions and the role of various AR subtypes, especially A2B 
receptor, are still not well defined in astroglial cells. 
In response to injury or infection, resident CNS cells generate pro-inflammatory cyto-
kines which, through the recruitment of immune cells and the autocrine activation of 
glial cells, may contribute to acute and chronic brain disease pathogenesis as well to 
psychiatric disorders (for review see Lucas et al., 2006). However, cytokines may have 
a dualistic role, with detrimental acute effects but also beneficial effects in long-term 
repair and recovery (Lucas et al., 2006).  
Recently, a functional cross-talk between cytokines and ARs has been demonstrated in 
different cell lines, including glial cells (Fredholm and Altiok 1994; Xaus et al. 1999; 
  
Khoa et al. 2001; Trincavelli et al. 2002); A2BRs, activated only under hypoxic or 
ischemic conditions, has been implicated in the control of cytokine release (Fiebich et 
al., 1996; Feoktistov et al., 2002; Zhong et al., 2004; Zhang et al., 2005; Kreckler et al., 
2006; Yang et al., 2006), that in turn can exacerbate or reduce inflammation.  
In particular, studies from our laboratory demonstrated that A2BRs are regulated by 
chronic treatment with the proinflammatory cytokine TNF-alpha (TNF-α) in astroglial 
cells: the exposure to TNF-α for 24 hours, although did not affect either the A2B mRNA 
and protein expression level, induced an up-regulation of the receptor responsiveness, 
thus impairing the agonist-mediated receptor phosphorylation and inducing, in turn, a 
delay in A2BR desensitization processes. The up-regulation of A2BR responsiveness 
plays an important role also in mediating chronic astrogliosis, thus suggesting a role for 
this receptor subtype in the long-term control of astrocytic function (Trincavelli et al., 
2004).  
While the effects elicited by A2Rs on proinflammatory cytokines have been extensively 
studied, even if with contrasting results, the cytokine (i.e. TNF-α) influence on adeno-
sine receptors has not been yet extensively investigated.  
Moreover, considering that the release of endogenous mediators during brain injuries 
mainly occurred in a few (1-4) hours, in order to better clarify the role of A2BR in the 
acute phase of brain damage, the aim of the present work has been: 
 
• To investigate the effects of the short-term TNF-α exposure on A2BR expression 
and functioning in human astrocytoma ADF cells and the intracellular pathways 
involved. 
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Chapter 2: 
Co-localization and functional cross-talk between A1 and 
P2Y1 purine receptors in rat hippocampus 
 
 
 
2.1 Abstract 
Adenosine and ATP, via their specific P1 and P2 receptors, modulate a wide variety of 
cellular and tissue functions, playing a protective or degenerative role in damage condi-
tions. Although in the brain, in general, adenosine inhibits excitability and ATP func-
tions as an excitatory transmitter in the central nervous system, recent data suggest the 
existence of a heterodimerization and a functional interaction between P1 and P2 recep-
tors in the brain, in particular the adenosine A1 (A1R) and the purine P2Y1 receptors 
(P2Y1R), playing a potentially important role in the purinergic signalling cascade. In the 
present work, we investigated A1R and P2Y1R sub-cellular localization/co-localization 
and their functional cross-talk at the membrane level in rat hippocampus. This is a par-
ticularly vulnerable brain area, which is sensitive to adenosine- and ATP-mediated con-
trol of glutamatergic transmission. The postembedding immuno-gold electron micros-
copy technique showed that A1R and P2Y1R are co-localized at the synaptic membranes 
and surrounding astroglial membranes of glutamatergic synapses.  
To investigate the functional cross-talk between the two types of purinergic receptors, 
we evaluated the reciprocal effects of their activation on their G protein coupling. 
P2Y1R stimulation impaired the ability of A1R coupling to G protein, whereas the 
stimulation of A1R increased the functional responsiveness of P2Y1R.  
The results demonstrated an A1R-P2Y1R co-localization at glutamatergic synapses and 
surrounding astrocytes and a functional interaction between these receptors in hippo-
campus, suggesting ATP and adenosine can interact in purine-mediated signalling. This 
interaction may be particularly important during pathological conditions, when large 
amount of these mediators are released. 
 
 
  
2.2 Introduction 
ATP and adenosine, via their specific P2 and P1 purinergic receptors (Fredholm et al., 
1994), mediate a wide variety of physiological processes including neuromodulation 
and neurotrasmission. Moreover, the purinergic system has been involved in many 
pathological and neurodegenerative conditions, in which massive release of ATP and, in 
turn, ADP and adenosine production, occur from damaged or dying cells, i.e. following 
ischemia, necrosis or injuries (Braun et al., 1998; Rathbone et al., 1999; Burnstock, 
2004). Several reports have described a dualistic neuroprotective-neuromodulatory role 
of ATP interacting with the specific ionotropic receptors (P2XR) and G-protein coupled 
receptors (GPCRs) (P2YR) (Fredholm et al., 1994). Among P2YRs, P2Y1 receptors 
(P2Y1R) appear to be of particular interest in patho-physiological mechanisms both with 
detrimental or beneficial effects (Franke and Illes, 2006). On the other hand, through the 
activation of the inhibitory A1 adenosine receptors (A1R) coupled to G proteins (Dun-
widdie and Masino, 2001), adenosine inhibits the release of excitatory neurotransmitters 
and decreases neuronal excitability, exerting a neuroprotective role (Wardas, 2002). 
Recent data have provided evidences for the existence of an association between A1 and 
P2Y1 receptors. In a co-transfected cell line model, Yoshioka and Nakata (2004) have 
demonstrated that these receptors directly interact to generate a hetero-oligomer, which 
has novel pharmacological and functional characteristics indicating a potential role in 
the purinergic-signalling cascade. Moreover, in specific rat brain regions (i.e. hippo-
campus) a high degree of co-localization of both these receptors has been demonstrated 
by immunofluorescence and immunoprecipitations experiments (Yoshioka et al., 2002). 
In CNS, although P2Y1 and A1 receptors have been involved in modulation of brain 
damage and contribute, alone or in combination, to neuro-degenerative/regenerative 
processes (Neary et al., 2003; Franke and Illes, 2006; Von Kugelgen, 2006), no data are 
at the present available on the precise localization/co-localization of A1 and P2Y1 recep-
tors at cellular and sub-cellular levels and on their reciprocal modulation/functional in-
teraction in native tissues following specific agonist activation. 
The hippocampus, a central component of the limbic system, has been identified as a 
brain area with a specific vulnerability to injuries, in particular to ischemia (Harry and 
Lefebvre d’Hellencourt, 2003). In the hippocampus, A1 and P2Y1 receptors are particu-
larly abundant (Gottlieb and Matute, 1997; Zhu et al., 2001; Ochiishi et al., 1999; 
Jimenez et al., 2000; Moran-Jimenez and Matute, 2000) and involved in the modulation 
  
of glutamate release (Rudolphi et al., 1992; Mendoza-Fernandez et al., 2000; Masino et 
al., 2002; Koizumi et al., 2003; Kawamura et al., 2004; Rodrigues et al., 2005; Jourdain 
et al., 2007), hence contributing to neurotransmission and neuro-degenerative and -
regenerative processes. 
In the present work, we investigated the localization/co-localization of A1R and P2Y1R 
in rat hippocampus, focusing in particular on the glutamatergic synapses and surround-
ing areas, using electron microscopic (EM) quantification of postembedding immu-
nogold labelling; this technique allows the precise localization of targets to be identified 
at sub-cellular resolution, on different parts of astrocytes and neurons. 
As a first step to investigate the functional A1 and P2Y1 receptors cross-talk, we studied 
the A1R activation following P2Y1R stimulation and vice versa in rat crude hippocam-
pal membranes. For this purpose the [35S]guanosine-5’-(γ-thio)-triphosphate 
([35S]GTPγS) binding assay (Lorenzen et al., 1993 and 1996) was used: the GTP bind-
ing represents the initial step of any GPCR activation and of the intracellular signalling 
cascade mediated by GPCRs (Lorenzen et al., 1996). 
 
 
2.3 Materials and methods 
 
2.3.1 Materials 
The A1R antibody (rabbit) was supplied by Alpha Diagnostic (San Antonio, TX, USA), 
while the P2Y1R antibody (rabbit) from Alomone Labs (Jerusalem, Israel). The A1R an-
tibody was raised against a 14 amino acid peptide corresponding to amino acid residues 
163-176 of the rat or human receptor protein, on the extracellular N-terminal domain. 
The P2Y1R antibody was raised against a 17 amino acid peptide 
(C)RALIYKDLDNSPLRRKS, corresponding to residues 242-258 of rat or human 
P2Y1R; the epitope location is in 3rd intracellular loop (i3) between the TM5 and TM6 
domains. Goat anti-rabbit immunoglobulins coupled to 10 nm or 15 nm gold particles 
were obtained from Aurion (Wageningen, The Netherlands). Secondary antibody goat 
anti-rabbit IgG-HRP conjugate was from Calbiochem (EMD Biosciences, affiliate of 
Merck KgaA, Darmstadt, Germany). Electrophoresis reagents were purchased from 
Bio-Rad (Hercules, CA, USA); full range Rainbow Molecular Weight Markers (range 
10–250 kDa) was obtained from Amersham Biosciences (Freiburg, Germany).  
  
[35S]GTPγS (specific activity 1000-1250 Ci/mmol) was purchased from Amersham Bio-
sciences Europe GmbH (Freiburg, Germany); adenosine deaminase (ADA) was from 
Roche Diagnostics GmbH (Mannheim, Germany). N6-cyclohexyl adenosine (CHA), 8-
cyclopentyl-1,3-dipropylxanthine (DPCPX), GDP, guanosine-5’-(γ-thio)triphosphate 
(GTPS), 2-methylthio-adenosine 5’-diphosphate (MeSADP), 2’-deoxy-N6-methyl 
adenosine 3’,5’-diphosphate (MRS2179), and protease inhibitors were obtained from 
Sigma Chemical Co (St. Louis, MO, USA). 
The protein concentration of the samples was established using the Protein Assay based 
on Bradford method from Bio-Rad (Hercules, CA, USA), using bovine serum albumin 
as a standard. All chemicals were of analytical grade and all solutions were prepared in 
demineralised and purified water obtained with the Milli-Q Millipore water purifying 
system (Millipore, Billerica, MA, USA). 
 
2.3.2 Postembedding Immunogold Cytochemistry 
Immunogold electron microscopy quantification was used to study A1 and P2Y1 recep-
tors in rat hippocampus, focusing on glutamatergic synapses. Receptor immunocyto-
chemistry was performed as previously described in Bergersen et al. (2005), with some 
modifications.  
Adult male Wistar rats (300 g, n=3) were anesthetized by pentobarbital i.p. and sub-
jected to transcardiac perfusion (50 ml/min for 20 min) with a solution of 4% parafor-
maldehyde and 0.1% glutaraldehyde in 0.1 M sodium phosphate buffer (NaPi) pH 7.4 at 
4ºC. The brains were left in situ overnight (4ºC). Then isolated hippocampal specimens 
were cryoprotected by immersion in graded concentrations of glycerol (10, 20 and 30%) 
in 0.1 M NaPi for 30 min. at each step and then overnight in 30% glycerol in 0.1 M 
NaPi at 4ºC. Samples were then plunged into liquid propane cooled at -190ºC with liq-
uid nitrogen in a Universal Cryofixation System KF80 (Reichert-Jung, Wien, Austria). 
For freeze-substitution (Muller et al., 1980), tissue samples were immersed in a solution 
of anhydrous methanol and 0.5% uranyl acetate overnight at -90ºC. The temperature 
was raised stepwise in 4ºC increments per hour from -90º to -45ºC, where it was kept 
for the subsequent steps. Tissue samples were washed several times with anhydrous 
methanol to remove residual water and uranyl acetate. The infiltration in Lowicryl 
HM20 went stepwise from Lowicryl/methanol 1:2, 1:1 and 2:1 (1 h each) to pure 
Lowicryl (overnight). For polymerization, the tissue was placed in a pre-cooled embed-
ding mall. The polymerization was catalyzed by UV light at a wavelength of 360 nm for 
  
2 days at -45ºC followed by 1 day at room temperature. Ultrathin sections (80 nm) were 
cut with a diamond knife on a Reichert-Jung ultramicrotome and mounted on nickel 
grids (300 mesh square, Electron Microscopy Sciences, USA) using an adhesive pen 
(Coat-Quick “G”, Electron Microscopy Sciences, USA). 
The sections were processed at room temperature in solutions of 0.05 M Tris HCl 
buffer, pH 7.4 containing 0.3% (for P2Y1R antibody) or 0.1% (for A1R antibody) NaCl 
and 0.1% Triton X-100 (TBST) and completed as stated below.  
After “etching” in sodium ethanolate to remove plastic from tissues, sections were left 
in TBST containing 2% human serum albumin (HSA) for 10 minutes and then incu-
bated overnight (20 hours) with primary antibodies against A1R (dilution 1:500: 2 
µg/ml) as well as for the P2Y1R (dilution 1:200: 4 µg/ml), diluted in TBST containing 
2% HSA. Sections were then incubated with goat anti-rabbit immunoglobulins coupled 
to 10 nm gold particles, diluted 1:20 in TBST with 2% HSA and, for A1R experiments, 
with 2 mg/ml polyethylene glycol. 
The ultrathin sections were processed both with single labelled and double labelled pro-
cedures. In double labelling experiments (Ottersen et al., 1992), sections were treated 
with the antibody against P2Y1R (dilution as above) in the first step (followed by 10 nm 
gold-labelled secondary antibody) and with the A1R antibody (dilution as above) in the 
next step (revealed by 15 nm gold-labelled secondary antibody): exposure to formalde-
hyde vapours (80ºC, 1 hour) was used between the two immunolabeling steps (Wang 
and Larsson, 1985), to destroy by formaldehyde the remaining free anti-IgG binding 
sites on the first primary and secondary antibodies. Potential cross-reactivity arising 
from the subsequent use of another secondary antibody that would be directed against 
the same species is prevented in this manner, allowing the simultaneous detection of 
two different antigens when using two primary antibodies from the same species. A1 
and P2Y1 receptors were distinguished by means of different gold particle sizes (10 nm 
for P2Y1R, 15 nm for A1R). The double labelling approaches gave similar patterns as 
the single labelling protocol.  
Negative control experiments also were performed, replacing the incubation with the 
primary antibodies with 2% HSA in TBST: staining was absent on sections that had 
been incubated in such a solution. Ultrathin sections were contrasted in uranyl acetate 
and lead citrate and observed in a Philips CM100 electron microscope.  
 
  
2.3.4 Immunocytochemistry Quantitative Analysis 
Electron micrographs were randomly taken in the hippocampus (magnification 34000x). 
Gold particles signalling both receptors (P2Y1R or A1R) were quantified as number of 
gold particles/µm2 at glutamatergic synapses (i.e., asymmetric synapses on dendritic 
spines) in the stratum radiatum of area CA1 and CA3, as well as in the juxtagranular 
part of the dentate molecular layer. The former are formed by terminals of ipsilateral 
(Schaffer collaterals) and commissural axon collaterals from CA3 pyramids, the latter 
by terminals of mossy cells in the dentate hilus. Only synapses with clearly visible post-
synaptic membrane and postsynaptic density were selected for analysis; essentially all 
synapses with this morphology are glutamatergic in these areas (for identification crite-
ria, see Gylterud Owe et al., 2005). Quantitative analyses were carried out on sections 
single labelled for either P2Y1R or A1R. Specific membrane compartments were defined 
and used for quantifications: they correspond to the presynaptic vesicles membranes, 
the membrane overlying the postsynaptic density (PSD), presynaptic membrane (oppo-
site to the PSD), pre- and post-perisynaptic membranes (corresponding to membrane 
lateral to the presynaptic active zone and the PSD, extending laterally by half the length 
of the PSD), extrasynaptic membranes (belonging to either presynaptic terminals or 
postsynaptic spines/dendrites but excluding the synaptic and perisynaptic membranes), 
postsynaptic intracellular membranes, astroglia membranes and mitochondrial outer 
membranes (Fig. 1) (cf. Bergersen et al., 2005).  
  
 
 
Fig. 1: Schematic illustration of a synapse between a presynaptic termi-
nal and a postsynaptic spine. Analysis of gold particle density (number 
of gold particles/µm2) was performed in specific membrane compart-
ments that were defined as: presynaptic vesicles membranes, the postsy-
naptic membrane overlying the postsynaptic density (PSD; red), pre-
synaptic membrane ‘active zone’ (i.e. opposite to the PSD; yellow), pre- 
and post-perisynaptic membranes on each side of the active zone (blue), 
extrasynaptic membranes (belonging to either presynaptic terminals or 
postsynaptic spines/dendrites but excluding the synaptic and perisynap-
tic membranes; green), postsynaptic intracellular membranes, astroglial 
plasma membranes (black) and mitochondrial outer membranes (brown). 
Note that the length of perisynaptic membrane considered corresponds 
to half the total length of the PSD, on each side (the same is valid for the 
presynaptic perisynaptic membrane). Figure modified from Bergersen et 
al. (2005). 
 
In addition, gross distribution of gold particles was recorded over the following location 
categories: presynaptic terminal, postsynaptic spine, synaptic cleft, astrocytes, mito-
chondria, extracellular and undefined.  
Particles located within 40 nm (perpendicular distance between the center of gold parti-
cle and the membrane) from different membranes were recorded: this distance was cho-
  
sen because 40 nm is about equal to the lateral resolution of the immunogold method, 
i.e., the max distance from the centre of the gold particle and the epitope, determined 
experimentally (Chaudhry et al., 1995; Nagelhus et al., 1998). The areas sampled were 
determined by grid point analysis (Gundersen H.J. et al., 1988; Gundersen V. et al., 
1998), and the densities expressed as gold particles / µm2. The distance between the 
centres of gold particles, representing receptors, and the external face of the postsynap-
tic density was determined along a perpendicular axis. All gold particles located within 
the postsynaptic spine and the presynaptic terminal were recorded; the width of the syn-
aptic cleft was also measured. The distribution of gold particles was compared with that 
of grid points placed randomly over the sampled area (Gundersen V. et al., 1998; 
Bergersen et al., 2003) in order to relate the distributions of A1R and P2Y1R to a ran-
dom distribution.  
 
2.3.5 Rat brain membrane Lysates and Western blotting 
Western blot analysis on rat hippocampus and full brain membranes has been used to 
confirm the specificity of the antibodies and the presence of the receptors, as further 
control. The whole brain or the hippocampus were removed from Wistar rats (200–300 
g; n=3) and immediately processed, keeping on ice. The tissues were suspended in 20 
volumes of ice-cold 50 mM Tris HCl, 2 mM MgCl2 buffer, pH 7.4, containing EDTA 1 
mM and protease inhibitors (Benzamidine 0.16 mg/ml, Trypsin inhibitor 0.03 mg/ml 
and Bacitracin 0.2 mg/ml) (buffer A). The tissues were then homogenized with a Poly-
tron homogenizer and after centrifugation (48000 g for 10 minutes at 4°C) the mem-
brane pellet were resuspended and re-homogenized in buffer A with ADA 2 U/ml to get 
a concentration of 50 mg/ml (from original tissue weight). After incubation for 30 min-
utes at 37°C, the samples were centrifuged at 4°C and each pellet was resuspended to 
use concentration, boiled in Laemmli solution for 5 minutes, centrifuged at room tem-
perature for 5 minutes and the supernatant used for electhrophoresis (or kept at –20°C 
until use). Tissue membrane homogenates (50 µg) were so processed by immunoblot 
following the method previously described (Trincavelli et al., 2004) with minor modifi-
cations. Briefly, samples were resolved by SDS-PAGE (10%), transferred to nitrocellu-
lose membranes and incubated with primary antibodies against A1 (1:500) or P2Y1 re-
ceptor (1:200) overnight at 4°C. Blots were developed using the Millipore Immobilon 
TM Western chemiluminescent HRP Substrate reagents (Millipore, MA, USA). 
 
  
2.3.6 Rat hippocampal membrane preparation for [35S]GTPγS binding assay 
Hippocampus, from male and female Wistar rats (200–300 g; n=3) were rapidly re-
moved and dissected on ice. Tissues were then homogenized in 20 volumes of ice-cold 
50 mM Tris–HCl, 2 mM MgCl2 buffer, pH 7.4, containing 0.1 mM dithiothreitol (DTT), 
protease inhibitors (phenylmethylsulfonyl fluoride 1 mM, benzamidine160 µg/ml, ba-
citracin 200 µg/ml, trypsin inhibitor 20 µg/ml) (buffer B) and 0.32 M sucrose, using a 
polytron homogenizer. The homogenate was centrifuged at 1000 g for 10 minutes at 
4°C: the supernatant was collected and centrifuged at 48000 g for 20 minutes at 4°C. 
The resulting pellet was resuspended in 10 volumes of buffer B and centrifuged again at 
48000 g for 20 min. at 4°C. The pellet was then resuspended in 5 volumes of the same 
buffer containing ADA 3 U/ml and incubated at 37°C for 30 min. to remove endoge-
nous adenosine. The membrane homogenate was centrifuged at 48000 g for 20 min. at 
4°C and the final pellet was stored as aliquots at −80°C until needed. The protein con-
centration of the sample was established. 
 
2.3.7 [35S]GTPγS binding assay on rat hippocampal membranes 
A1R coupling to G proteins was evaluated assessing the ability of the selective A1R-
agonist CHA to stimulate [35S]GTPγS binding in rat hippocampal membranes (HC) pre-
treated for 10 minutes with buffer alone (Control HC) or 100 nM MeSADP (MeSADP-
treated HC). In parallel, aliquots of control membranes were also pre-incubated with the 
A1R selective antagonist DPCPX (50 nM) for 10 minutes before the CHA-stimulation. 
In the same way, P2Y1R/G protein coupling was evaluated assessing the ability of the 
agonist MeSADP to stimulate [35S]GTPγS binding in membranes pre-treated for 10 
minutes with buffer alone (Control HC) or 100 nM CHA (CHA-treated HC). In parallel, 
control membranes were also treated with the P2Y1R selective antagonist MRS2179 (10 
µM), for 10 minutes before MeSADP-stimulation (MRS2179-treated HC). 
Rat hippocampal membranes were resuspended in 25 mM Hepes NaOH, pH 7.4, 5 mM 
MgCl2, 1 mM EDTA, 100 mM NaCl (buffer C) containing 1 mM DTT. Aliquots of HC 
(10 µg) were incubated in 0.1 ml of buffer C containing ADA (0.2 U/ml), 10 µM GDP 
and 0.3 nM [35S]GTPγS in the presence (stimulated) and absence (basal) of a range of 
concentrations of CHA or MeSADP (0.1 nM-10 µM). ADA was added to assay to 
eliminate the interference of endogenous adenosine in the basal [35S]GTPγS binding. 
Incubation was carried out at 25°C for 2 hours. Unspecific binding was defined in the 
  
presence of 100 µM GTPγS and it resulted less than 10% of total binding. Binding reac-
tions were terminated by rapid filtration under vacuum through Whatman GF/C glass 
fiber filters (Millipore Corporation): the filters were washed three times with 3 ml of 50 
mM Tris HCl, 5 mM MgCl2, pH 7.4 and then counted in a scintillation cocktail. The 
concentration-dependent increase in specific [35S]GTPγS bindings by agonists was ex-
pressed as a percent increase above the basal unstimulated binding (fixed as 100%). All 
the experiments were performed in duplicate. 
 
2.3.8 Data analysis  
Data from immunogold cytochemistry localization were statistically analysed with One-
Way ANOVA and/or with Student’s t-test (two-tails, unpaired) by program GraphPad 
PRISM Version 4.00 (GraphPad Software, San Diego, CA, USA) and reported as 
mean±SEM; statistical significance refers to results where P <0.05 was obtained.  
Agonist dose-response curves were analyzed by the non-linear regression curve-fitting 
computer program GraphPad PRISM Version 4.00 and the EC50 values were derived. 
Data are reported as mean±SEM of four different experiments (performed in duplicate). 
Statistical analysis (Student’s t-test, two tails, unpaired) was performed using the 
GraphPad Prism program; significance refers to results where P <0.05 was obtained. 
 
 
2.4 Results 
 
2.4.1 Immunolocalization 
Postembedding immunogold electron microscopy was used to study A1 (Fig. 2) and 
P2Y1 (Fig. 3) receptors in rat hippocampus, focusing on glutamatergic synapses (i.e., 
small terminals with asymmetric synapses on dendritic spines) and surroundings glia. 
For quantitative analysis single labelled sections, were randomly selected from CA1 and 
CA3 stratum radiatum, and juxtagranular part of the dentate molecular layer, regions 
that are particularly high in nerve terminal glutamate and glutamatergic markers (e.g., 
Cotman et al., 1987). As no overt differences were noticed between the areas, they were 
analysed together. Both A1R and P2Y1R were detected on synaptic and glial membranes 
(Fig. 2-3). 
  
 
 
 
FIG. 2: Localization of purinergic receptors in glutamatergic synapses 
in rat hippocampus by immunogold labelling. Electron micrographs of 
sections single labelled for A1R are illustrated by examples from CA1 
stratum radiatum (A main picture, B), CA3 stratum radiatum (A inset, 
C) and hilus (D). Note that A1Rs were detected both in the postsynaptic 
density (black arrows) and in the presynaptic (active zone) membranes 
at glutamatergic synapses and in glia (*).  
Scale bar: 100 nm. m= mitochondria; S= postsynaptic dendritic spine; t= 
presynaptic axon terminal; * = astroglia.  
 
  
 
 
Fig. 3: Localization of purinergic receptors in glutamatergic synapses in 
rat hippocampus by immunogold labelling. Electron micrographs of sec-
tions single labeled for P2Y1R are illustrated by examples from area 
dentata (A main picture), CA1 stratum radiatum (A inset), hilus (B) and 
neuropil layer (close to granular cell layer, C). Note that P2Y1Rs were 
detected on synaptic and glial membranes: both in the postsynaptic den-
sity (black arrows) and in the presynaptic (active zone) membranes at 
glutamatergic synapses and in glia (*). Scale bar: 100 nm. m= mito-
chondria; S= postsynaptic dendritic spine; t= presynaptic axon terminal; 
* = astroglia.  
 
 
  
Immunolabeling negative control experiments have been also performed; omitting the 
primary antibodies abolished labelling (Fig. 4), indicating a low unspecific signal due to 
the detection system. 
 
 
 
 
Fig. 4: Omission of primary antibody 
prevented all gold labelling (pictures 
from CA3 and CA1 stratum radiatum).  
Scale bar: 100 nm. m= mitochondria; S= 
postsynaptic dendritic spine; t= pre-
synaptic axon terminal; * = astroglia. 
 
 
 
 
 
A1R and P2Y1R antibody specificity was further addressed by western blot analysis, us-
ing rat whole brain and hippocampus membrane fractions (Fig. 5): rat tissues were 
tested with the same antibodies used for immunocytochemistry. Results confirmed the 
presence of the two receptors and their antibody specificity. A1R immunoreactive 
bands, around 80 kDa, correspond to the dimer form of A1Rs (79 kDa) while the P2Y1R 
multi-line pattern shows immunoreactive bands at 76, 40 and 35 kDa, corresponding to 
dimeric and monomeric variants, in agreement with literature data (Hoffmann et al., 
1999; Blum et al., 2002; Moore et al., 2002; Waldo and Harden, 2004). The main band 
is that around 40-42 kDa, while the lower band is likely a partially degraded product of 
P2Y1R and the higher a dimer. In particular, Waldo and Harden (2004) reported that the 
  
incubation at higher temperature increased the occurrence of P2Y1R multimeric immu-
noreactive species, with higher molecular mass. A multimeric pattern, due to the sample 
extraction protocol, is also in agreement with reports of supplier company (Alomone 
Lab), which indicates that the antibody can produce one band in rat brain extracts under 
certain conditions, indicating that the different bands shown in Fig. 5B are not due to 
false immunoreactivity directed against other proteins than P2Y1Rs. 
 
 
 
Fig. 5: Western blot analysis of A1R (A) and P2Y1R (B), in rat whole 
brain and hippocampus membrane homogenates. Rat tissue membranes 
were lysed, separated (50 µg) by 10% polyacrylamide SDS-PAGE and 
tested with the same antibodies used for immunocytochemistry.  
 
 
The receptor distribution and localization was quantified in different subcellular struc-
tures (Fig. 6 A-B). The localization of both receptors was expressed as the areal density, 
the number of gold particles/µm2, in different structures in the vicinity of hippocampal 
glutamatergic synapses, determining the area by point analysis (Gundersen, H.J. et al., 
1988). Assuming the mitochondria do not contain the receptors, the density of gold par-
ticles over mitochondria may be taken to represent unspecific background binding of 
antibodies. Both A1R and P2Y1R were highly concentrated in the synaptic cleft area and 
in adjacent astrocytes, which were the only compartments significantly higher than mi-
tochondria (Fig. 6 A-B).  
  
 
 
FIG. 6: Distribution of immunogold particles indicating A1R (A) or 
P2Y1R (B) in different intra- and extracellular compartments. Note that 
both receptors are enriched at synapses and astroglia, compared to all 
other compartments. Data, from single labelling experiments, report the 
localization of receptors as the density (gold particles/µm²; mean±SEM) 
in the different compartments in the vicinity of hippocampal glutamater-
gic synapses (randomly selected, from n = 3 animals; 5 grids analyzed 
for A1R and 6 grids for P2Y1R); the areas of the compartments were 
measured by point analysis (see Methods). The numbers of gold parti-
  
cles on each structure are, in order: 323, 230, 1, 52, 24, 31, 15 for A1R; 
330, 311, 5, 112, 35, 31, 32 for P2Y1R. Areas analysed for each com-
partments are, in order: 10.8; 7.7; 0.1; 1.1; 0.2; 0.6; 1.3; 1.0 m2 for 
A1R; 12.1; 8.8; 0.2, 2.1; 0.2; 0.9; 1.7; 0.8 µm2 for P2Y1R. A) A1R. ** 
P<0.01 all compartments compared to mitochondria (One-way ANOVA, 
Dunnett’s multiple comparison test). Synaptic cleft is significantly dif-
ferent compared to all other domains (# P<0.01, One-way ANOVA, 
Tukey’s multiple comparison test). Astrocytes and synaptic cleft col-
umns showed higher receptor density compared to mitochondria (§ 
P<0.05, Student’s t-test, 2-tails, unpaired). B) P2Y1R. * P<0.05, ** 
P<0.01 all domains compared to mitochondria (One-way ANOVA, 
Dunnett’s multiple comparison test). Synaptic cleft is significantly dif-
ferent compared to all other domains: # P<0.001 vs. all except Astro-
cytes and P<0.01 vs. astrocytes (One-way ANOVA, Tukey’s multiple 
comparison test). 
 
 
Because the spatial resolution of our immunolabeling method is of the same order of 
magnitude as the distance between different compartments / membranes in the tissue, an 
individual gold-particle cannot be directly ascribed to any single structure. Therefore, 
the association of gold particles with membranes was analysed in several different 
ways.  
First, we investigated the distribution of gold particles associated with each kind of cel-
lular membrane, in the vicinity of hippocampal synapses, recording only particles 
within a distance ≤10 nm from each kind of membrane to minimize “cross firing” ef-
fects from immunoreactivity in nearby structures. Immunogold single-labelling of hip-
pocampal sections showed that A1R (Fig. 7 A) as well as P2Y1R (Fig. 7 B) are mainly 
associated with presynaptic membranes, postsynaptic membranes overlying the PSD 
and astroglial membranes. The high A1R presence on presynaptic-perisynaptic mem-
branes (* P<0.05, One-way ANOVA, value vs. mitochondria) could be influenced from 
receptors that are located in the active zone or as “reserve” (Rebola et al., 2003); any-
way the values on perisynaptic and extrasynaptic membranes, both pre- and post-, can 
be influenced from receptors that are instead on astroglia membranes, for the tight con-
tact between these and neurons. No other columns differed from the background level, 
as indicated by the density of gold particles over mitochondrial outer membranes 
(P>0.05, One-way ANOVA). Further, values at the presynaptic membrane and at the 
membrane covering the PSD were significantly different compared to all other loca-
tions, confirming that A1Rs are associated with these membranes.  
  
For P2Y1R, the density was significantly higher in PSD than in other membrane com-
partments, except for the presynaptic and astroglial membranes (# P<0.01, One-way 
ANOVA), meaning these compartment are particularly enriched in the P2Y1Rs.  
 
 
  
 
FIG. 7: Distribution of immunogold particles indicating A1R (A) or 
P2Y1R (B) over different categories of cellular membranes in the vicin-
ity of hippocampal synapses. Both receptor types are enriched over pre-
synaptic as well as postsynaptic membranes and over astroglial mem-
branes. Only particles located within a distance ≤10 nm from each kind 
of membrane were recorded, to minimize “cross firing” effects from 
immunoreactivity in nearby structures. The data are presented in the 
same way, and are from the environments of the same synapses, as are 
the data in FIG. 3. The sizes of the areas sampled for gold particles (±10 
nm on each side of the membrane) were determined by point  
analysis. Areas analysed for each category are, in order: 3.8; 0.5; 0.3; 
1.4; 0.7; 0.3; 1.1; 0.3; 0.6; 0.6 µm2 for A1R; 5.1; 0.8; 0.3; 1.6; 0.8; 0.4; 
2.0; 0.6; 1.2; 0.7 µm2 for P2Y1R. The numbers of gold particles within 
10 nm from each membrane column are, in order: 196, 126, 22, 98, 141, 
19, 54, 32, 57, 12 for A1R; 260, 81, 15, 101, 124, 26, 74, 36, 116, 27 for 
P2Y1R. The density of gold particles over the outer membrane of mito-
chondria gives an estimate of the background level. A) * P<0.05, ** 
P<0.01, all columns compared to mitochondria background level (One-
way ANOVA, Dunnett’s multiple comparison test). Presynaptic mem-
brane and PSD are significantly different compared to all other mem-
brane categories (# P<0.01, One-way ANOVA, Tukey’s multiple com-
parison test). B) ** P<0.01 all columns compared to mitochondria back-
ground level (One-way ANOVA, Dunnett’s multiple comparison test). 
PSD is significantly different compared to all other columns except for 
presynaptic membranes and astroglial membranes (# P<0.01, One-way 
ANOVA, Tukey’s multiple comparison test). 
 
 
We then compared the distribution of gold particles representing A1R and P2Y1R with 
the distribution of points spread randomly over the pictures (Fig. 8). The gold parti-
cles/random points ratio was determined at different distances, from different membrane 
domains, sorted into bins (10-20-30-40 nm). For the shortest distance (10 nm) bins, the 
highest ratio values (about 2) were obtained, for both A1R and P2Y1R, at presynaptic 
active zone membranes, postsynaptic membranes overlying the PSD and astroglial 
membranes (Fig. 8 A-B), i.e., the same membrane domains that show the highest label-
ling according to the analysis of Fig. 7. Also several other neuronal membranes, but not 
mitochondrial outer membranes, had ratios higher than one, consistent with a moderate 
enrichment of receptors in them. As previously noted, the densities in perisynaptic and 
extrasynaptic membranes could be influenced from gold particles in active zone or in 
astroglial membranes. 
  
 
 
FIG. 8: Histogram of gold particles/random points ratio: gold particles 
were grouped in bins depending the distance (10-20-30-40 nm) from 
each kind of membrane, at hippocampal glutamatergic synapses and sur-
rounding glia. The % of the total number of gold particles that occurred 
in each bin was divided by the % of the total random points (within 40 
nm distance) that occurred in the same bin: the ratio gives the distribu-
tion of receptors relative to a random distribution. A ratio >1 for the 
shorter distance bins (10 and 20 nm), indicates a close association with 
the membrane observed. Note the higher ratios (arrows) for short dis-
tances at presynaptic active zone membranes, postsynaptic membranes 
overlying the PSD and astroglial membranes, for both A1R (A) and 
P2Y1R (B). 
  
The average distance of immunogold particles from membranes was then measured and 
compared with a random distribution (Fig. 9). Note that for both A1R (A) and P2Y1R 
(B) the mean distance of gold particles is shorter than that of random points in all mem-
branes, except in mitochondria outer membranes (which represent an estimate of back-
ground labelling). 
 
 
 
  
FIG. 9: Average distances of immunogold particles from membranes. 
The values are the mean±SEM of the distances of gold particles (white 
bars) or random points (black bars) located within a distance ≤40 nm 
from different membrane categories, in the vicinity of glutamatergic 
synapses in rat hippocampus. Note that for both A1R (A) and P2Y1R (B) 
the mean distance of gold particles is shorter than that of random points 
in all membranes, except in mitochondria outer membranes (which rep-
resent background labelling). The total number of particles counted is: 
for A1R gold particles: 286; 241; 34; 159; 230; 38; 101; 37; 91; 241; for 
P2Y1R gold particles: 392; 238; 41; 183; 247; 47; 145; 44; 207; 44. For 
A1 random points: 457; 212; 46; 313; 218; 48; 187; 39; 149; 177; for 
P2Y1 random points: 457; 127; 47; 270; 132; 55; 269; 60; 162; 63. 
 
 
To further dissect the synaptic localization of A1R and P2Y1R, all the hippocampal glu-
tamatergic synapses previously analyzed were processed to record the % distribution of 
both receptors as a function of the perpendicular distance from the postsynaptic mem-
brane overlying the PSD (Fig. 10). The % distribution of A1Rs in the synaptic area (Fig. 
10 A, left) showed that A1Rs are located over both the PSD and the presynaptic mem-
brane, although the density is highest over the latter. The influence of the extracellular 
location of the epitope recognized by the A1R-antibody may have contributed to the 
high level of gold particles located in the synaptic cleft. A1R-gold particles situated over 
the synaptic cleft were preferentially associated with the presynaptic membrane (Fig. 10 
A, right), indicating a shared distribution of the receptor between the pre- and post-
synaptic sides. P2Y1Rs were relatively more distributed towards the PSD membrane 
(Fig. 10 B, left), compared to A1Rs, and gold-particles in the cleft showed less enrich-
ment on the presynaptic side (Fig. 10 B, right). These results are consistent with a high 
degree of co-localization of the two types of receptor, but with relatively less of P2Y1R 
than of A1R on the presynaptic side. 
 
  
 
 
FIG. 10: Distribution of immunogold particles across the synaptic cleft. 
The histograms on the left show the % of gold particles representing 
A1R (A) and P2Y1R (B) in the synaptic area, as a function of the dis-
  
tance up to 100 nm from the postsynaptic membrane at the PSD. The 
distance between the centre of gold particles and the external face of the 
PSD was determined along a perpendicular axis (cf. Fig. 1). Positive 
columns (10 to100 nm) represent the postsynaptic spine; negative col-
umns (-20 to -100 nm) the presynaptic terminal; the -10 nm column 
represents the synaptic cleft (i.e. position 0 to -10 nm). The actual width 
of the synaptic cleft was 11.5±0.4 nm (mean±SEM, n= 79). Numbers of 
gold particles considered in the analysis are: n= 266 for A1R; n= 296 for 
P2Y1R. All synapses previously analyzed have been processed in this 
analysis. Note that the highest particle counts for A1R as well as P2Y1R 
were in the PSD bin. The histograms on the right show the distribution 
of immunogold particles within the synaptic cleft. The % of the total 
number of gold particles located in the synaptic cleft (n= 41 for A1R; n= 
28 for P2Y1R), in function of the distance from the outer face of the 
PSD; pre-synaptic side = position between 0 and -3 nm; post-synaptic 
side = between -6 and -10 nm; middle of cleft = between -3 and -6 nm. 
The distributions within the synaptic cleft indicate that both A1R (A) and 
P2Y1R (B) are located pre- as well as post-synaptically. 
 
 
In conclusion, A1R and P2Y1R are co-localized in synaptic and astroglial membranes in 
glutamatergic synapses and surrounding glial membranes in the hippocampus. The 
quantitative analyses of single labelling data were confirmed by the qualitative analysis 
of double labelling experiments (Fig. 11). The double labelling approach gave similar 
patterns as the single labelling protocol: the receptors were detected together in the 
same structures and both were associated with synaptic and astroglial membranes. 
 
  
 
Fig. 11: Qualitative co-localization of P2Y1R and A1R in glutamatergic 
synapses (randomly selected) and surrounding glia, in rat hippocampus 
CA3 (A, B) and CA1 (C, D) stratum radiatum. Electron micrograph of a 
section double labelled for A1R (large gold particles, 15 nm) and P2Y1R 
(small gold particles, 10 nm). The double labelling approach gave simi-
lar patterns as the single labelling protocol. Note that the receptors were 
detected together in the same structures. A1R and P2Y1R appeared co-
localized (qualitative data) on the PSD (black arrows) and on astroglia 
(*). Scale bar: 100 nm. m= mitochondria; S= post synaptic spine; t= pre-
synaptic terminal; * = astroglia. 
 
 
 
2.4.2 Functional assays 
In HC the effect of P2Y1R activation on A1R/G protein coupling was measured by 
evaluating the ability of the A1R agonist CHA to stimulate G protein activation follow-
ing 100 nM MeSADP pre-incubation (for 10 minutes). In Control HC, CHA stimulated 
G protein activation with an EC50 of 30.60±3.99 nM (Fig. 12). The CHA-mediated ef-
fect was abolished in the presence of the selective A1R antagonist DPCPX (50 nM), 
confirming A1R specific activation (data not shown). 
Membrane pre-incubation with 100 nM MeSADP induced a right-shift of the CHA 
dose/response curve (EC50=106.26±16.39 nM), suggesting a significant impairment in 
A1R-G protein coupling when P2Y1 receptor is activated (t-test, two-tails, unpaired: ** 
P<0.01 for EC50 of MeSADP-treated HC vs. Control HC) (Fig. 12). 
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FIG. 12: Effect of P2Y1R activation on A1R agonist-mediated G protein 
coupling. Dose-response curves of CHA-stimulated [35S]GTPγS binding 
were obtained incubating Control HC (■) and MeSADP-treated (100 
nM) HC (●) with different agonist concentration (0.1nM-10µM). Data 
are expressed as % of [35S]GTPγS specific binding over basal value, set 
to 100%, and are reported as mean±SEM (n=4), all performed in dupli-
cate. Student’s t-test, two-tails, unpaired: ** P<0.01 EC50 of Control HC 
vs. MeSADP-treated HC. 
 
 
On the other hand, the A1R activation effect on P2Y1R/G protein coupling was meas-
ured by evaluating the ability of the P2Y1R agonist MeSADP to stimulate G protein ac-
tivation in the absence or the presence of 100 nM CHA (preincubated for 10 minutes). 
In Control HC, MeSADP stimulated [35S]GTPγS binding with an EC50 of 0.851±0.147 
nM (Fig. 13). 
To test the selectivity of MeSADP for P2Y1 receptor subtype in our model, we also 
stimulated HC in presence of the selective P2Y1R antagonist 10 µM MRS2179 (prein-
cubated for 10 minutes). MRS2179 blocked MeSADP-mediated G protein coupling in 
HC (Fig. 13), showing this G protein activation is selectively driven by P2Y1R and 
other P2Y receptors sensitive to MeSADP (P2Y12-13) have no significantly signal com-
ponent in rat hippocampus. Membrane CHA pre-incubation induced an significant in-
crease in MeSADP potency to activate P2Y1R-G protein coupling, with an EC50 of 
  
0.393±0.058 nM (t-test; two-tails, unpaired: * P<0.05), without affecting significantly 
the G protein coupling efficacy level of the agonist dose/response curve (Fig. 13). 
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FIG. 13: A) Effect of A1R activation on P2Y1R agonist-mediated G pro-
tein coupling. Dose-response curves of MeSADP-stimulated [35S]GTPγS 
binding were obtained incubating Control HC (■) and CHA-treated (100 
nM) HC (●) with different agonist concentration (0.1nM-10M). Data 
are expressed as % of [35S]GTPγS specific binding over basal value set 
to 100% and are reported as mean±SEM (n=4), all performed in dupli-
cate. Student’s t-test, two-tails, unpaired: * P<0.05 EC50 of Control HC 
vs. CHA-treated HC. B) Aliquots of HC were also pre-exposed to the se-
lective P2Y1R antagonist MRS2179 (10µM) (MRS2179-treated HC) 
(▲) and then stimulated by MeSADP (0.1nM-10µM). Data are ex-
pressed as % of [35S]GTPγS specific binding over basal value set to 
100% and are reported as mean±SEM (n=4), all performed in duplicate. 
  
2.5 Discussion 
 
2.5.1 Immunolocalization and co-localization 
This is the first study on A1R and P2Y1R localization and co-localization in hippocam-
pus by postembedding immunogold electron microscopy analysis: this high resolution 
technique is able to show the precise subcellular localization of receptors in different 
subcellular compartments and cell populations (e.g., Bergersen et al., 2003). The 
purinergic receptors proved to be mainly associated with membrane domains. Single la-
belling immunolocalization data showed a significant enrichment of both A1R and 
P2Y1R mainly in postsynaptic membranes at the PSD, in presynaptic active zones, and 
in astroglial membranes at glutamatergic synapses and surrounding glia in the rat hip-
pocampus. The same conclusion was arrived at by analysing the data in different ways, 
in order to partly overcome the limits posed by “cross firing” effects antigen located in 
closely spaced neighbouring membranes. Because of these, the exact labelling densities 
of the individual membranes cannot be determined. While the three membrane catego-
ries mentioned contain higher levels of both of the purinergic receptors studied, low or 
moderate labelling may exist in other membrane categories. The data suggest that there 
may be relatively higher densities of A1R than of P2Y1R at the presynaptic compared to 
the postsynaptic membrane. Part of this observed difference might be attributable to the 
fact that the antibodies were to extracellular and intracellular epitopes, respectively. 
However, the main conclusion is that the two receptor types are similarly distributed, 
compatible with a high degree of co-localization. This was born out by double labelling 
experiments which showed A1R and P2Y1R to be closely spaced along synaptic and 
glial membranes. 
Our high resolution data serve to extend and reconcile previous reports obtained with 
lower resolution methods. Thus A1R immunoreactivity has been reported in hippocam-
pus both at pre- and post-synaptic terminals but not at glial cells (Ochiishi et al., 1999); 
an immunohistochemical study in the rat hippocampus has concluded that A1Rs were 
mostly located in axons rather than in nerve terminals (Swanson et al., 1995), whereas 
work on synaptosomal fractions (Rebola et al., 2003) has suggested that A1Rs are en-
riched in nerve terminals and are mainly located in synapses, both in the presynaptic ac-
tive zone and in the PSD membranes. P2Y1R immunoreactivity has been found in as-
troglia and in different kinds of neurons in hippocampus (Moran-Jimenez & Matute, 
  
2000), especially in ischemic sensitive areas while at the same time another study re-
ported a striking neuronal localization for P2Y1R (human brain, Moore et al., 2000). 
P2Y1Rs have been reported to be present and active on astrocytes all around the brain 
(Franke et al., 2001; Volontè et al., 2006). A high degree of co-localization of A1R and 
P2Y1R has been found in rat hippocampus by immunofluorescence experiments but 
without cellular and sub-cellular identification (Yoshioka et al., 2002).  
We studied A1Rs and P2Y1Rs in the hippocampal region considering the fact that the 
hippocampus has been identified as a major target site for numerous disease processes 
(Bachevalier & Meunier, 1996; Harry & Lefebvre d’Hellencourt, 2003), and consider-
ing the generally assumed involvement of purinergic receptors in patho-physiological 
mechanisms and in the modulation of brain damage (Fredholm, 1997; Franke et al., 
2006b). Ischemia, to which hippocampus is particularly vulnerable, produces a marked 
increase in glutamate within the brain extracellular space (Benvensiste et al., 1984; 
Hagberg et al., 1985), thereby triggering excitotoxic injuries (Choi & Rothman, 1990). 
Because of the importance of glutamate in pathological conditions and because its re-
lease, in neurons and in astrocytes, is modulated both through A1R (Rudolphi et al., 
1992; Masino et al., 2002) and P2Y1R (Rodrigues et al., 2005; Franke et al., 2006a; 
Jourdain et al., 2007), the present study was focused on A1R-P2Y1R localization and 
co-localization within and in the vicinity of glutamatergic synapses. 
Our results provide direct morphological support for the previous suggestions that both 
of these receptors contribute to and interact in the modulation of glutamate release (Ru-
dolphi et al., 1992; Mendoza-Fernandez et al., 2000; Masino et al., 2002; Kawamura et 
al., 2004; Rodrigues et al., 2005). 
 
2.5.2 Functional interaction 
The functional interaction of A1Rs and P2Y1Rs suggested by the morphological obser-
vations was subsequently confirmed through measurement of G protein activation initi-
ated by the A1R-agonist CHA or the P2Y1R-agonist MeSADP, respectively, and modi-
fication of the response through preincubation with the other agonist. Because the re-
ceptors on study are coupled to different G protein subtypes (Munshi et al., 1991; 
Yoshioda and Nakata, 2004) and to different intracellular signalling pathways, the 
[35S]GTPγS binding method was chosen to investigate the A1R-P2Y1R interaction and 
their reciprocal modulation at the membrane level, allowing any change in their func-
  
tioning to be determined independently of the second messenger systems activated 
(Lorenzen et al., 1996). 
According to literature data (Gao et al., 2003; Dixon et al., 2004; Niebauer et al., 2005), 
the selected agonist preincubation times and concentrations pre-stimulating A1R and 
P2Y1R (100 nM CHA and 100 nM MeSADP, respectively) allow a selective and maxi-
mal receptor activation. The EC50 for CHA in stimulating A1R-G protein coupling 
ranged around 30 nM: CHA-mediated G protein activation was abolished in the pres-
ence of the highly selective A1R antagonist DPCPX (Klotz, 2000), confirming further 
the selective A1R activation. Although CHA has been reported to block [3H]DPCPX 
binding at A1R with a Ki around 5 nM in rat hippocampus (Maemoto et al., 1997), 
higher EC50 values for different A1R agonists in the [35S]GTPS binding assay have 
been found (Lorenzen et al., 1996), correlating with the low affinity state values (KL) of 
the receptor. In line with these findings, even an EC50 around 100 nM has been reported 
for CHA in a [35S]GTPγS assay in CHO cells transfected with the human A1 receptor 
(Cordeaux et al., 2004). 
On the other hand, in our results, MeSADP showed subnanomolar potency in stimulat-
ing P2Y1R. Because of the absolute potency of nucleoside tri- and di-phosphates for 
P2Y receptors is dependent on the levels of receptor protein expression, typical EC50 
values are not easily defined for specific agonists at particular P2Y receptor subtypes in 
different tissue preparations and cell lines (Volontè et al., 2006). In accordance with our 
results, low nanomolar EC50 values have been reported for human P2Y1R expressed in 
astrocytoma 1321N1 cells (Palmer et al., 1998; Niebauer et al., 2005) and rat P2Y1R, 
expressed in HEK 293 cells, was reported to be functionally activated by MeSADP at 
subnanomolar concentrations (Vohringer et al., 2000). 
MeSADP is the principal agonist not only at P2Y1R but also at P2Y12-13 receptors, that 
are coupled to Gi proteins and are expressed (mRNA) in the brain (Hollopeter et al., 
2001; Zhang et al., 2002; Sasaki et al., 2003), even if not at high level in the hippocam-
pus (Fumagalli et al., 2004; Amadio et al., 2006). To confirm that in our model the Me-
SADP-mediated G protein activation was mainly driven by P2Y1R, we also stimulated 
hippocampal membranes in the presence of the selective P2Y1R antagonist MRS2179: 
MRS2179 was able to block the MeSADP-mediated response, confirming the P2Y1R 
involvement since no antagonistic effects have been demonstrated on P2Y12-13 receptors 
at the MRS2179 concentrations used (Moro et al., 1998; Von Kugelgen, 2006). 
  
The results obtained on A1R-P2Y1R cross-talk in hippocampus showed that, stimulating 
one receptor, the functioning of the other was changed: in particular, P2Y1R pre-
activation caused an impairment in A1R-G protein coupling with a reduction in A1R 
agonist potency; on the other hand, A1R pre-activation induced an increase in P2Y1R 
functional coupling to G proteins. Our results are in agreement with the previously re-
ported reduction in the A1R ligand affinities in cells co-expressing both A1R and P2Y1R 
(Yoshioka et al., 2001). Various studies have reported that ATP, massively released af-
ter brain damage, acts to modulate not only its own P2Y1R but also A1R (Hourani et al., 
1991; Piper and Hollinsworth, 1996; Masino et al., 2002; Fredholm et al., 2003; 
Yoshioda and Nakata, 2004). 
The functional consequence of this A1-P2Y1 receptor cross-talk is complicated by the 
availability time and the balance of their endogenous ligands. Extracellular ATP, rap-
idly available due to direct release into the extracellular space, and adenosine, available 
after ATP breakdown, are tightly regulated by rapid metabolism and re-uptake 
(Zimmermann, 2000) and can be differently regulated in physiological or pathological 
conditions: in fact the ecto-nucleotidase chain has proved to be up-regulated in ischemi-
cally damaged tissues (Braun et al., 1998). 
Data, at present, have shown the A1R -P2Y1R interaction mechanism may be used to 
fine-tuning the purinergic signalling, including the inhibition of neurotransmission (Na-
kata et al., 2004). Considering the new information available and the A1R and P2Y1R 
involvement in glutamatergic transmission modulation (Mendoza-Fernandez et al., 
2000; Masino et al., 2002; Kawamura et al., 2004; Rodrigues et al., 2005), we can 
speculate that there is an A1R-P2Y1R cross-talk in rat hippocampal glutamatergic syn-
apses and surroundings glia, where these receptors are co-localized. This might there-
fore be one of the mechanisms for the adenine nucleotide-mediated inhibition of gluta-
matergic neurotransmitter release. Therefore, as suggested for adenosine A1 and A2A re-
ceptors in striatal (Ciruela et al., 2006) and hippocampal (Rebola et al., 2005) glutama-
tergic nerve terminals, a cross-talk/heteromerization of A1R-P2Y1R could exert a fine-
tuning modulation of glutamatergic neurotransmission, providing a switch mechanism 
by which low and high concentrations of adenosine or purines could regulate glutamate 
release. 
Because of the high level of complexity of purinergic receptor signalling (Volontè et al., 
2006) and the regulation of glia–neuron and glia–glia communications by extracellular 
  
purines (Franke et al., 2006b; Jourdain et al., 2007), the present work opens the way to 
further investigation of the A1R-P2Y1R system interaction: on astrocyte cell popula-
tions, which communicate bidirectionally with neurons (Newman, 2003; Bezzi et al., 
2004; Jourdain et al., 2007) and contribute to damage or to regeneration after CNS in-
jury (Franke et al., 2001; Anderson et al., 2003). 
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Chapter 3: 
Functional cross-talk between A1 and P2Y1 purine receptors 
in human astroglial cells 
 
 
 
3.1 Introduction 
The purinergic system is involved in many physiological and pathological events, espe-
cially because ATP massive release occurs from damaged or dying cells following brain 
ischemia, necrosis or reduced perfusion of brain tumors (Ravelic and Burnstock, 1998; 
Rathbone et al., 1999; Burnstock, 2004). Extracellular ATP levels are strictly regulated 
by the balance between release and degradation, through a family of ectoenzymes that 
rapidly (Dunwiddie et al., 1997) idrolyzes or interconverts extracellular nucleotides, 
thereby terminating their signalling action or producing new active metabolites (ADP, 
AMP or adenosine), which can continue or functionally antagonize some effects of ATP 
(Zimmermann, 2000). Purinergic nucleotides participate in cell differentiation, prolif-
eration and survival as well as in degeneration and death (Franke and Illes, 2006), thus 
acting through their specific P2 receptors, subclassified into P2X (ligand-gate cation-
selective channels receptors) and P2Y (G-protein coupled receptors, GPCRs) subtypes 
(Fredholm et al., 1994). In particular, P2Y1 receptors (P2Y1Rs), which are selectively 
activated by ADP nucleotides and act via Gq/11 protein/ phospholipase C/ Ca+2 pathway, 
are involved, both with detrimental and/or beneficial effects (Franke and Illes, 2006), in 
platelet aggregation (Fabre et al., 1999), in apoptotic events (Sellers et al., 2001; Ma-
medova et al., 2006), in microglial inflammatory functions (Von Kugelgen, 2006), in 
brain ischemic damages (Lammer et al., 2004) and trauma (Neary et al., 2003; Franke 
et al., 2004), in Alzheimer’s disease structures in hippocampus (Moore et al., 2000), in 
the induction of proliferation and reactive astrogliosis (Franke et al., 2001; 2004). 
Adenosine is principally a regulator of cellular homeostasis, thus acting through its spe-
cific P1 adenosine receptors (A1, A2A, A2B and A3) (Ribeiro et al., 2003). It decreases 
neuronal excitability, especially through the activation of inhibitory A1 receptors (A1R), 
which are the most abundant among the adenosine receptors in the brain (Dunwiddie 
and Masino, 2001; Ochiishi et al., 1999). The A1R, which is functionally coupled to a 
  
pertussis toxin-sensitive Gi/o protein, acts via adenylyl ciclase inhibition, activation of 
K+ channels and inhibition of Ca+2 influx (Fredholm et al., 2001). 
Whereas the neuroprotective role of adenosine analogues active at the A1 receptor sub-
type have been known for several years (Wardas, 2002), the role of P2Y1 receptor have 
not been fully characterized enough if there are indications about important pathological 
functions (reviewed by Franke and Illes, 2006), according to the fact that purine-
mediated induction and maintenance of astrogliosis can be considered as a first response 
to limit the loss of neuronal tissue after insults (Franke et al., 2004).  
P2Y1 and A1R receptors, both widely expressed around the brain (Lenz et al., 2000; 
Jimenez et al., 2000; Moran-Jimenez and Matute, 2000; Ochiishi et al., 1999) seems lo-
calized in the same region, thus suggesting a potential interaction between these recep-
tors in precise areas. Literature reports have showed A1 and P2Y1 receptors interact both 
synergically and functionally (Hourani et al., 1991; Mendoza-Fernandez et al., 2002; 
Fredholm et al., 2003; Kawamura et al., 2004). Moreover data supporting the existence 
of a high co-localization and of a heteromeric complex with novel pharmacological and 
functional properties between A1 and P2Y1 receptors have been reported in co-
trasfected cells and in rat brain tissues (Yoshioda et al., 2002; Yoshioka and Nakata, 
2004).  
In particular, previous results from our group showed a high co-localization between A1 
and P2Y1 receptors on glutamatergic synaptic and astroglia membranes in rat hippo-
campus and a functional interaction at G protein coupling level between these receptors 
in hippocampal crude preparations (see Chapter 2). 
The purinergic system has an high level of complexity and this is further augmented, 
considering that receptors can cross-talk and also form homomers/heteromers (Nakata et 
al., 2004) and that the composition of the oligomers profoundly affects the biological 
response of these receptors (Volontè et al., 2006). Heterodimerization of GPCRs may 
results: in changes in the affinity of the receptors for ligands; in mechanisms where one 
ligand modulates the efficacy and/or potency of another ligand specific for the 
neighbouring receptor; in the localization of downstream signalling components to spe-
cific areas on the cell; in aggregation of downstream signalling or switching off/down 
one of receptors (Rios et al., 2001). 
The functional implications of the P2Y1R heterodimerization with the A1R and in par-
ticular of the P2Y1R activation influence on the neuroprotective A1R role still await fur-
ther characterizations. 
  
In the present work we investigated the A1R-P2Y1R cross-talk in human astroglial cells, 
in particular we evaluated the effects of P2Y1R activation on A1R-mediated G protein 
coupling and intracellular functioning. Although classically thought to mediate a sup-
portive role, there is now evidence to demonstrate that astrocytes actively participate in 
informing processes by affecting intrinsic properties of synapses (Newman, 2003) and 
are involved in the most integrated functions of the central nervous system. Based on 
these data and considering astroglia contributes to damage but also to regeneration and 
neurogenesis after injuries in CNS (Anderson et al., 2003), we envisage that the charac-
terization of A1R-P2Y1R cross-talk in astrocytes may have important functional impli-
cations. 
 
 
3.2 Materials and methods 
 
3.2.1 Materials 
[35S]GTPγS (specific activity 1000-1250 Ci/mmol) was purchased from Amersham Bio-
sciences Europe GmbH (Freiburg, Germany) and [3H]DPCPX (specific activity 116 
Ci/mmol) from Perkin Elmer Life Sciences (Boston, MA, USA). GDP, GTPγS, CHA, 
MeSADP, DPCPX, MRS2179, R-PIA, Pertussis-toxin (PTX), protease inhibitors and 
rabbit IgG were obtained from Sigma Chemical Co (St. Louis, MO, USA). ADA was 
from Roche Diagnostics GmbH (Mannheim, Germany). Cell culture media RPMI1640 
and Dulbecco’s modified Eagle’s medium (DMEM F-12), fetal bovine serum, L-
glutamine, penicillin and streptomycin were purchased from Cambrex Bio-Science 
(Verviers, Belgium). Dimethyl sulfoxide of microbiological quality was purchased from 
Fluka (Buchs, Switzerland). 
Electrophoresis reagents were purchased from Bio-Rad (Hercules, CA, USA). A1R an-
tibody (rabbit) was supplied by Alpha Diagnostic (San Antonio, TX, USA), while the 
P2Y1R antibody (rabbit) from Alomone Labs (Jerusalem, Israel). Secondary antibody 
goat anti-rabbit IgG-HRP conjugate was from Calbiochem (EMD Biosciences, affiliate 
of Merck KgaA, Darmstadt, Germany). Protein A SepharoseTM was from Amersham 
Pharmacia Biotech AB (Uppsala, Sweden). The protein concentration of the samples 
was established by the Protein Assay based on Bradford method from Bio-Rad (Hercu-
les, CA, USA), using bovine serum albumin as a standard. All other reagent grade 
  
chemicals were supplied from standard commercial sources and all solutions were pre-
pared in demineralised and purified water obtained with the Milli-Q Millipore water pu-
rifying system (Millipore, Billerica, MA, USA). 
 
3.2.2 Cell culture 
Human astrocytoma cells (ADF) were kindly supplied by Prof. Maria Pia Abbracchio 
(Department of Pharmacological Sciences, University of Milan). ADF cells (Malorni et 
al., 1994) were grown adherently and maintained in culture in standard conditions (37°C 
in humidified atmosphere, 95% humidity, 5% CO2) in RPMI 1640 medium supple-
mented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 1% non-essential amino acids (complete medium) as previously de-
scribed (Trincavelli et al., 2002). When cells were grown at confluence, cells were 
treated with Trypsin 0,25% for few minutes to detach cells from surface and then com-
plete medium was added to neutralize trypsin; cells were then collected, centrifuged at 
180 g for 5 minutes, resuspended in new complete medium and expanded. All opera-
tions were carried out under laminar flux hut, with an UV sterilization system. 
 
3.2.3 Cell treatments 
When the cells were grown to sub-confluence, the complete medium was replaced with 
fresh RPMI1640 or DMEM F-12 (only for cAMP assay) medium containing treatment-
compounds. 
Cells were treated without (Control) or with different MeSADP concentrations (1nM-
10M) for different times (5-60 minutes) (MeSADP) and then harvested for im-
munoblotting analysis, [3H]DPCPX binding assay, [35S]GTPγS assay and cAMP assay.  
Further experiments were carried out after the pre-incubation of cells with the selective 
P2Y1R antagonist MRS2179 (10 µM) for 15 minutes before the MeSADP exposure 
(MRS2179+MeSADP). In selected experiments, the inhibition of Pertussis-toxin 
(PTX)-sensitive Gi proteins was obtained by incubating cells with 100 ng/ml PTX for 
18 hours before membrane preparation (Fumagalli et al., 2004). 
 
3.2.4 Lysates, immunoprecipitates and Western blotting  
The presence of A1R and P2Y1R in control and MeSADP-treated ADF cells was as-
sessed by Western blot analysis of separated proteins from cell lysates. Control and 
MeSADP-treated ADF cells were processed by immunoblot following the method pre-
  
viously described (Trincavelli et al., 2004), with some modifications. Separation on 
SDS-PAGE was performed according to the Laemmli procedure. 
Treated and untreated ADF cells were scraped and lysed in PBS (NaH2PO4 9.1 mM, 
Na2HPO4 1.7 mM, NaCl 150 mM, pH 7.4) containing 0.5% Deoxycholic acid sodium 
salt, 0.1% SDS, 1% Nonidet P-40 and proteases inhibitors (phenylmethylsulfonyl fluo-
ride 1 mM, sodium orthovanadate 1 mM, aprotinin 0.04 mg/ml) (RIPA buffer); cell lys-
ates were so centrifuged to get rid of large cellular debris (15000 g for 45 minutes at 
4°C). 
Cell lysates (50 µg), after being resuspended in Laemmli solution and boiled for 5 min-
utes, were resolved by SDS-PAGE (10%), transferred to nitrocellulose membranes and 
probed overnight at 4°C with anti-A1R (2 µg/ml) or anti-P2Y1R (4 µg/ml) antibody. 
Membranes were then incubated with the corresponding peroxidase-linked secondary 
antibody (goat anti-rabbit), washed and developed using the Millipore Immobilon TM 
Western chemiluminescent HRP Substrate reagents (Millipore, MA, USA). Density of 
immuno-reactive bands was quantified by densitometric scanning and by a gel docu-
mentation system (ImageJ Program, National Institutes of Health, USA). 
Immunoprecipitation/co-immunoprecipitation experiments were also carried out to 
evaluate the dimerization between A1 and P2Y1 receptors. For co-immunoprecipitation 
experiments, cell lysates (1 mg) were pre-cleared by incubating directly with Protein A 
Sepharose (1h at 4°C). Samples were then centrifuged for 10 minutes at 4°C (14000 g): 
the supernatants were incubated with anti-A1 or anti-P2Y1 receptor antibody 
(3 µg/sample) overnight at 4°C under constant rotation and then immunoprecipitated 
with Protein A Sepharose (2 hours at 4°C). Immuno-complexes, after being washed, re-
suspended in Laemmli solution and boiled for 5 minutes, were resolved by SDS-PAGE 
(10%), transferred to nitrocellulose membranes and probed overnight at 4°C with pri-
mary antibody anti-A1R (2 µg/ml). Membranes, after incubation with the secondary an-
tibody, were developed using the Millipore chemiluminescent reagents (see above). Un-
specific immunoprecipitation was assessed using non-immune rabbit IgG (3 µg, same 
amount of antibody). 
For molecular mass determination, polyacrylamide gels were calibrated by Full range 
Rainbow Molecular Weight Markers within the range of 10-250 kDa (Amersham Bio-
sciences, Freiburg, Germany). 
 
  
3.2.5 ADF membrane preparation for [35S]GTPγS and [3H]DPCPX binding assays 
After different treatments, ADF cells were scraped, lysed with 5 mM Tris HCl, 2 mM 
EDTA, pH 7.4 (Lysis buffer) and homogenized in a polytron homogenizer, keeping on 
ice. Cell homogenates were then centrifuged at 48000 g at 4°C: membrane pellets were 
then re-suspended in assay buffer A (50 mM Tris HCl, 10 mM MgCl2, pH 7.4) or B (25 
mM Hepes, 100 mM NaCl, 5 mM MgCl2, EDTA 1 mM, pH 7.4), re-homogenized and 
the protein concentration was determinated. Aliquots of cell membranes were then used 
for assays or stored at -80°C, after being quickly frozen in N2. 
 
3.2.6 [3H]DPCPX binding assay 
The influence of P2Y1R activation on A1R equilibrium binding parameters was evalu-
ated by [3H]DPCPX saturation binding studies: the ligand affinity (Kd) and the maximal 
density of A1R binding site (Bmax) were determinated. For saturation binding studies, 
Control and MeSADP-treated ADF cell membranes were resuspended in binding buffer 
A (50 mM Tris HCl, 10 mM MgCl2, pH 7.4) containing ADA (2 U/ml). Then, ADF 
membrane fractions (20 µg) were incubated for 3 hours at 25°C in binding buffer A 
containing ADA 0.2 U/ml and different [3H]DPCPX concentrations (0.5-15 nM). 
Moreover competition curves of MeSADP were performed by binding assays in the 
presence of 2.5 nM [3H]DPCPX: ADF cell membranes (40 µg) were incubated for 3 
hours at 25°C in binding buffer A containing ADA 0.2 U/ml, [3H]DPCPX 2.5 nM and 
different MeSADP (0.1nM-10µM) concentrations.  
Non-specific binding was determined in presence of 100 µM R-PIA and it resulted less 
than 10% of total binding. Binding reactions were terminated by rapid filtration under 
vacuum through Whatman GF/C glass fiber filters (Millipore Corporation): the filters 
were washed three times with 3 ml of binding buffer A and then counted in a scintilla-
tion cocktail. For test-compounds dissolved in DMSO, the final solvent concentration 
never exceed 2%. 
 
3.2.7 [35S]GTPγS binding assay on ADF cell membranes 
A1R-G protein coupling was evaluated assessing the ability of the specific A1R agonist 
CHA to stimulate [35S]GTPγS binding. Cell membranes were suspended in binding 
buffer B (25 mM Hepes, 100 mM NaCl, 5 mM MgCl2, EDTA 1 mM, pH 7,4) contain-
ing DTT 1 mM, BSA 0.1% and ADA (2 U/ml). Aliquots of membrane homogenate (20 
  
µg) were incubated for 30 minutes at 30°C in 0.1 ml of binding buffer B containing 10 
µM GDP and 0.2-0.3 nM [35S]GTPγS and stimulated with CHA (0.1-100 nM) or Me-
SADP (1 µM). ADA was added to assay to eliminate the interference of endogenous 
adenosine in the basal [35S]GTPγS binding. Non-specific binding was determined in 
presence of 20 µM GTPγS and it resulted less than 10% of total binding. Binding reac-
tions were terminated by rapid filtration under vacuum through Whatman GF/C glass 
fiber filters (Millipore Corporation): the filters were washed three times with 3 ml of 
binding buffer B and then counted in a scintillation cocktail. The results were expressed 
as a percent increase above the basal unstimulated binding (fixed as 100%). All the ex-
periments were performed in duplicate.  
 
3.2.8 cAMP assay on ADF cells 
Two days before the experiment, cells (50000 cells/well) were seeded in 24-well plate, 
to have sub-confluence conditions in 48 hours. On the day of the cAMP assay, ADF 
cells were treated with or without MeSADP (1 µM) for different time points (0-60 min-
utes) and then placed in fresh DMEM F-12 medium with 2 U/ml ADA and 10 µM 
phosphodiesterases inhibitor 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone (Ro 
201724) for 15 minutes at 37°C. Cells were then stimulated with 10 µM forskolin for 5 
min and with CHA (0.5 nM-1 µM) or MeSADP (0.01 nM-1 µM) for 10 minutes. 
After incubation, cells were lysed with HCl 0,1 M for 15 minutes at 37°C and assayed 
for cellular cAMP accumulation using the competitive cAMP enzyme immunoassay 
system kit (Sigma–Aldrich, St. Louis, MO, USA), following the manufacture's instruc-
tion. Briefly cell lysates were centrifuged at 1000 g for 10 minutes and supernatant were 
used for assay. Luminescence was read at 405 nm with a Wallac Victor2TM 1420 Multi-
label plate reader (Perkin Elmer Life Sciences). For test-compounds dissolved in 
DMSO, the final solvent concentration never exceed 2%. 
 
3.2.9 Data analysis 
A non-linear multipurpose curve-fitting computer program (Kell RadLig, Elsevier-
Biosoft, USA) was used for analysis of saturation data. Data from agonist dose–
response were analyzed by the non-linear regression curve-fitting computer program 
GraphPad Prism Version 4.00 (GraphPad Software, San Diego, CA, USA) and the EC50 
  
values were derived. The Ki values for competition binding assays were calculated from 
the EC50 values by the Cheng and Prusoff equation (Cheng and Prusoff, 1973).  
Data are reported as mean±SEM of three different experiments (performed in dupli-
cate). Statistical analysis was performed with One-Way ANOVA (Tuckey's multiple 
comparison test) or Student’s t-test (two-tails, unpaired), using GraphPad Prism pro-
gram: significance refers to results where P <0.05 was obtained. 
 
 
3.3 Results 
 
3.3.1 Immunoprecipitation and Western-blotting  
The presence of A1AR and P2Y1R on ADF cells was addressed by Western blot analy-
sis. Lysates from Control and 1 µM MeSADP (30 min)-treated cells were resolved by 
SDS-Page and probed with the specific A1R and P2Y1R primary antibodies. The results 
demonstrated both A1AR and P2Y1R were expressed in ADF cells (Fig. 1). The A1R 
immunoreactive band was detected at the apparent molecular mass of 39 kDa (Fig. 1A): 
furthermore, the A1R expression level was not affected by MeSADP exposure. The 
principal P2Y1R immunoreactive bands were instead around 54 and 48 kDa (Fig. 1B), 
with an additional band around 95 kDa.  
 
 
 
Fig. 1: Western Blot analysis of A1R (A) and P2Y1R (B), in lysates of 
Control and MeSADP (1µM for 30’)-treated ADF cells. Receptors were 
lysed, resolved by 10% polyacrilamide SDS-PAGE and tested with spe-
cific antibodies.  
 
  
The existence of A1R-P2Y1R heteromeric complexes, in basal conditions, was thus in-
vestigated by co-immunoprecipitation experiments (Fig. 2). Untreated ADF cells were 
lysed and then A1R or P2Y1R were immunoprecipitated by primary antibody and Pro-
tein A, resolved by SDS-PAGE and probed with the anti-A1R antibody. The results 
showed A1Rs and P2Y1Rs are able to interact to form a heteromeric complex in basal 
condition, in ADF cells. In fact it has been possible to detect the A1R immunoreactive 
band in P2Y1R-immunoprecipitate sample, thus suggesting the anti-P2Y1R antibody 
was able to immunoprecipitate A1R protein and so the two receptors are covalently 
bound on cell membranes.  
 
 
 
Fig. 2: Immunoprecipitation of A1R and P2Y1R. A1R or P2Y1R were 
immunoprecipitated by incubating cell lysates with anti-A1R or –P2Y1R 
antibody and Protein A, processed by SDS-PAGE and probed with the 
anti-A1R antibody. Left panel: Unspecific immunoprecipitation of rabbit 
IgG solution (3 µg/lane). 
 
 
3.3.2 [3H]DPCPX Binding Assay 
The influence of P2Y1R activation on A1R equilibrium binding parameters was evalu-
ated by [3H]DPCPX saturation binding experiments. 
As illustrated in Fig. 3, Scatchard analysis of [3H]DPCPX saturation binding data dem-
onstrated the presence of a homogenous population of A1AR binding sites in ADF cells 
with a Kd value of 8.8±0.7 nM and a Bmax value of 1340±110 fmol/mg proteins. Cell 
pre-incubation with 1 µM MeSADP for 30 minutes induced a significant decrease in the 
A1R radioligand affinity constant value (Kd= 4.1±0.2 nM; * P<0.05 vs. Control, Stu-
  
dent’s t-test) without affecting significantly the receptor density value (Bmax= 1140±95 
fmol/mg proteins; P>0.05 vs. Control, Student’s t-test). Results suggested the A1R affin-
ity for its antagonist ligand increases when P2Y1R is also activated, thus confirming fur-
ther that the A1R expression level was not affected by MeSADP exposure. 
 
 
 
Fig. 3: [3H]DPCPX Scatchard analysis assay. Cell membranes, obtained 
from Control (A) and MeSADP (1 µM for 30’)-treated (B) cells, were 
incubated for 3 hours at 25°C with different [3H]DPCPX concentrations 
  
(0.5-15 nM). The figure depicted a representative Scatchard analysis of 
[3H]DPCPX saturation binding data; results are reported as mean±SEM 
(n=3). * P<0.05 Control vs. MeSADP, Student’s t-test. 
 
 
To evaluate whether MeSADP effects were caused by a direct interaction of P2Y1R 
agonist on A1R binding site, competition experiments were performed using different 
MeSADP concentrations (0.1nM-10µM). As showed in Fig. 4, MeSADP resulted not 
able to compete with [3H]DPCPX for binding to A1R site, thus showing no direct inter-
action with A1R binding sites.  
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Fig. 4: Membranes, obtained from Control ADF cells (■), were incu-
bated for 3 hours at 25°C with increasing MeSADP concentrations (1 
nM-10 µM) and 2.5 nM [3H]-DPCPX. Data are expressed as mean±SEM 
of % of specific binding (n=3). 
 
 
 
3.3.3 [35S]GTPγS binding assay 
As first step, we investigated the basal G protein activation level in Control and 1 µM 
MeSADP (30’) pre-treated cells. Cell treatment with MeSADP didn’t induce any sig-
nificant alterations in the basal [35S]GTPγS binding value, thus suggesting it has no ef-
  
fect on G protein functional state (Fig. 5): Control= 15.26±3.1 fmol/mg protein, Me-
SADP= 16.48±4.8 fmol/mg protein (P>0.05 Control vs. MeSADP, Student’s t-test). 
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Fig. 5: Basal G protein activation levels in membranes from Control 
(white) and 1µM MeSADP-treated (grey) ADF cells. Data are expressed 
as fmol/mg of proteins and represent the mean±SEM of three experi-
ments. P>0.05 Control vs. MeSADP, Student’s t-test. 
 
 
The effect of P2Y1R pre-activation on A1R/G protein coupling was then assessed by 
evaluating the ability of the selective A1R agonist CHA to stimulate [35S]GTPγS bind-
ing in Control and 1 µM MeSADP-treated cell membranes. 
In control ADF cells, CHA stimulated G protein activation with an EC50 value of 
2.47±0.43 nM. CHA-mediated effects were abolished in the presence of the selective 
A1R antagonist DPCPX (50 nM), thus confirming the agonist response is mediated by 
A1R activation (data not shown).  
Cell pre-incubation with 1 µM MeSADP for 30 min induced a right-shift of the agonist 
dose/response curve, with an EC50 value for CHA of 10.72±3.22 nM (** P<0.01 Con-
trol vs. MeSADP; One-way ANOVA) (Fig. 6). Data suggested a significant impairment 
in the A1R/G protein coupling when P2Y1 receptor is activated.  
  
To discern if the functional interaction between these receptors at level of receptor/G 
protein coupling occurred at membrane sites was mediated by intracellular signalling 
pathways, aliquots of Control cell membranes were incubated directly in the assay with 
MeSADP 1 µM, 10 minutes before CHA stimulation: EC50 for CHA resulted 9.68±1.38 
nM (** P<0.01 Control+MeSADP on assay vs. Control; P>0.05 Control+MeSADP on 
assay vs. MeSADP; One-way ANOVA) (Fig. 6). The effects of P2Y1R on A1 receptor-
G protein activation occurred at membrane level and were not mediated by intracellular 
signalling pathways. 
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Fig.6: Effects of MeSADP-mediated P2Y1R activation on A1R/G-
protein coupling. Cell membranes, from Control (■) and MeSADP (1µM 
for 30’)-treated (▲) ADF cells, were prepared and the ability of the A1R 
agonist CHA to stimulate GTPγs binding was assessed. Similar results 
were obtained incubating directly the membranes with MeSADP 1µM 
on the assay (▼). Data are expressed as % of basal [35S]GTPγS binding 
(set to 100%) and represent the mean±SEM (n=3). 
*** P<0.001 Control vs. MeSADP; ** P<0.01 Control vs. Con-
trol+MeSADP on assay; P>0.05 MeSADP vs. Control+MeSADP on as-
say (Student’s t-test).  
 
 
  
Moreover, to ascertain the MeSADP effects were really mediated by P2Y1 receptor sub-
type, we also stimulated ADF cells in presence of the selective P2Y1R antagonist 
MRS2179 (10 µM). MRS2179 was able to block the MeSADP-mediated impairing ef-
fect on A1R-G protein coupling in ADF cells (* P<0.05 MRS2179+MeSADP vs. Me-
SADP; P>0.05 MRS2179+MeSADP vs. Control; One-way ANOVA) (Fig. 7) and to re-
store the A1R-G protein coupling level as in Control cells. Data showed MeSADP ef-
fects are mediated by P2Y1R and didn’t involve other P2Y receptors present on astro-
cytes and sensitive to the agonist (i.e. P2Y12-13). 
 
 
Fig. 7: P2Y1R selectivity of MeSADP-mediated effects on A1R/G-
protein coupling impairment. Cell membranes, from Control (white 
squares), MeSADP (1µM for 30’)-treated (grey squares) and 10 µM 
MRS2179 plus MeSADP-treated (black squares) ADF cells, were stimu-
lated with 100 nM CHA to asses GTPγs binding. Data are expressed as 
percentage of basal [35S]GTPγS binding (set to 100%) and represent the 
mean±SEM (n=3). 
* P<0.05 MRS2179+MeSADP vs. MeSADP; P>0.05 
MRS2179+MeSADP vs. Control; # P<0.01 MeSADP vs. Control (One-
way ANOVA). 
 
 
  
Moreover, we investigated the MeSADP-stimulated coupling to Gi protein, to assess the 
possible interference of other P2YRs (i.e. 12-13), that are achievable by MeSADP and 
coupled to Gi proteins, in ADF cells. The 1 µM MeSADP-stimulated G protein coupling 
was assayed in control and 18 hour PTX-treated cells (Fig. 7), in which PTX treatment 
inhibited Gi protein functioning. The G protein activation levels didn’t differ signifi-
cantly between treated and untreated cells (P>0.05 Control vs. PTX, Student’s t-test). 
The results confirmed further the MeSADP activity in ADF cells is P2Y1R-selective 
and not mediated by other P2YRs; nevertheless results also suggested the MeSADP-
mediated P2Y1R coupling to Gi protein component is of not relevance and the A1R-G 
protein reduced coupling was not caused by modulation of Gi activation state by Me-
SADP. 
 
 
 
Fig. 8 P2Y1R coupling to Gi protein. The 1 µM MeSADP-stimulated G 
protein coupling was assayed in Control (white) and 18 hours PTX (100 
ng/ml)-treated (grill pattern) ADF cells. Following incubation, mem-
brane fractions were prepared and the ability of 1 µM MeSADP to 
stimulate GTPγs binding was assessed. Data are expressed as % of basal 
[35S]GTPγS binding (set to 100%) and represent the mean±SEM (n=3). 
P>0.05 Control vs. PTX, Student’s t-test. 
 
 
 
 
 
  
3.3.4 cAMP Assay  
The effect of P2Y1R pre-activation on A1R functional responsiveness was then assessed 
by evaluating the ability of the selective A1R agonist CHA to inhibit cAMP production 
in Control and MeSADP-treated cell membranes. 
As a first step, we investigated the effects of MeSADP treatment (1 µM for 30’) on 
basal and 10 µM FSK-stimulated cAMP levels. As showed in Fig. 9, MeSADP pre-
treatment per se didn’t influence cAMP levels in ADF cells, both in basal and FSK-
stimulated conditions (P>0.05 Control vs. MeSADP and Control+FSK vs. Me-
SADP+FSK; Student’s t-test). 
 
 
Fig. 9: Basal (full) and 10 µM FSK-stimulated (stripes) cAMP level in 
Control (white) and MeSADP treated (grey) cells. Results are expressed 
as % of FSK-stimulated cAMP on basal levels (set to 100%) and as 
mean±SEM (n= 3). P>0.05 Control vs. MeSADP, Student’s t-test. 
 
 
Then the A1R functional responsiveness was evaluated by measuring the ability of CHA 
to inhibit cAMP production stimulated by 10 µM FSK.  
In Control cells CHA inhibited the production of cAMP in a concentration dependent 
manner with an EC50 value of 1.085±0.17 nM (Fig. 11).  
  
Cell exposure to MeSADP (1 µM) induced a significant decrease in A1R functional re-
sponsiveness in a time dependent manner with a maximal effect following 30 minutes 
incubation (Fig. 10). These results suggested 1 µM MeSADP was able to induce a 
short-term P2Y1R-mediated heterologous A1AR desensitization. 
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Fig. 10: MeSADP exposure time-dependence effects on A1R functional 
responsiveness. Cells were treated with or without 1 µM MeSADP for 
different times (5-60 min); then the ability of 10 nM CHA to inhibit 10 
µM FSK-stimulated cAMP accumulation was investigated. Data are ex-
pressed as percentage of cAMP on 10 µM FSK-stimulated level (set to 
100%) and represent the mean±SEM (n=3). 
 
 
When cells were pre-treated with MeSADP (1 µM for 30 min) a significant reduction in 
the CHA potency was detected (EC50= 4.306±0.51 nM; *** P<0.001 Control vs. Me-
SADP-treated cells, Student’s t-test; Fig. 11). Data suggested a significant impairment 
of A1R functional coupling to adenylyl cyclase pathway when P2Y1 receptor is acti-
vated.  
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Fig. 11: CHA concentration-dependence effects on A1R functional re-
sponsiveness. The ability of the A1R agonist CHA to inhibit the 10 µM 
FSK-mediated cAMP production was assessed in cell membranes, from 
Control (■) and MeSADP(1µM for 30’)-treated (▲) ADF cells. Data are 
expressed as percentage of cAMP on 10 µM FSK-stimulated level (set to 
100%) and represent the mean±SEM (n=3). Control EC50= 1.085±0.17 
nM; MeSADP EC50= 4.306±0.51 nM. *** P<0.001 Control vs. Me-
SADP, Student’s t-test. 
 
 
To confirm the selectivity of MeSADP for P2Y1Rs, we also stimulated ADF cells in 
presence of the selective antagonist MRS2179 (10 µM). MRS2179 blocked the Me-
SADP-mediated A1R functional impairment (** P<0.01 MeSADP vs. 
MRS2179+MeSADP and vs. Control; P>0.05 MRS2179+MeSADP vs. Control, One-
way ANOVA), thus restoring the A1R functional responsiveness up to control levels 
(P>0.05 MRS2179+MeSADP vs. Control) (Fig. 12). Data showed the MeSADP-
mediated A1R functional impairment is driven by P2Y1R and doesn’t involve any other 
P2Y receptor sensitive to MeSADP and expressed in astrocytes (i.e. P2Y12-13). 
 
 
  
 
 
 
Fig.12: P2Y1R selectivity of MeSADP-mediated effects on A1R respon-
siveness impairment. Cell membranes, from Control (white), MeSADP 
(1µM for 30’)-treated (grey) and 10 µM MRS2179 plus MeSADP-
treated (black) ADF cells, were stimulated without (full colour) or with 
100 nM CHA (stripes) to asses the 10 µM FSK-mediated cAMP inhibi-
tion. Data are expressed as percentage of cAMP on 10 µM FSK-
stimulated level (set to 100%) and represent the mean±SEM (n=3). 
** P<0.01 MRS2179+MeSADP and Control vs. MeSADP; P>0.05 
MRS2179+MeSADP vs. Control (One-way ANOVA). 
 
 
In the end, to investigate if P2Y1R was able to act also through the A1R-adenyly cyclase 
pathway, as reported by Yoshioka and co-workers (2001), in ADF cells we evaluated 
the ability of MeSADP to inhibit 10 µM FSK-mediated intracellular cAMP production 
in ADF cells. Increasing concentrations of MeSADP resulted not able to reduce cAMP 
  
levels: these results suggest P2Y1R is not able to act through adenyly cyclase signalling 
pathway in ADF cells (Fig. 13). 
 
 
 
Fig. 13: MeSADP concentration-dependence effects on 10 µM FSK-
stimulated cAMP intracellular levels in ADF cells. Membranes, obtained 
from Control ADF cells, were stimulated without or with increasing Me-
SADP concentrations (0.01 nM-1 µM), in the presence of 10 µM FSK. 
Data are expressed as percentage of cAMP on 10 µM FSK-stimulated 
level (set to 100%) and represent the mean±SEM of three different ex-
periments. P>0.05 all columns vs. FSK basal (One-way ANOVA).  
 
 
 
 
 
 
 
 
 
 
  
3.4 Discussion 
The present study investigated the A1R-P2Y1R cross-talk in human astroglial ADF 
cells: in particular alterations in the A1R binding and functioning parameters following 
the P2Y1R activation by its selective agonist MeSADP were evaluated. 
As a first step, it has been demonstrated that ADF cells express both purinergic A1 and 
P2Y1 receptors. Immunoblotting results, from cell lysates, showed the A1R (39 kDa) 
and the P2Y1R multi-line pattern (48-54-95 kDa), in agreement with literature data 
(Hoffmann et al., 1999; Sellers et al., 2001; Moore et al., 2002; Waldo and Harden, 
2004). The main band is that around 54 kDa, while the lower band (48 kDa) is likely a 
partially degraded product of P2Y1R and the higher a multimeric form. Waldo and 
Harden (2004) reported that the incubation at higher temperature increased the occur-
rence of P2Y1R multimeric immunoreactive species, with higher molecular mass; 
moreover, the 95 kDa band is in agreement with the antibody data sheet. The mul-
timeric pattern, due probably to sample preparation protocols and to detergent use, is 
also in agreement with a report from the antibody supplier company (Alomone Labs). 
The co-immunoprecipitation results indicated that A1R is able to interact with P2Y1R to 
form a heteromeric complex in ADF cell membranes, just in basal condition, as previ-
ously reported in A1-P2Y1 receptor co-transfected cell model and in rat brain (Yoshioka 
et al., 2002). 
The functional interaction between A1 and P2Y1 receptors was then investigated among 
the effects of ADF cell treatment with the P2Y1R agonist MeSADP on A1R functional 
responses. According to preliminary experiments and to literature data concerning 
P2YR agonist potency in different systems (reviewed by Volontè et al., 2006), the 1 
M MeSADP cell exposure for 30 minutes was chosen to stimulate a maximal P2Y1R 
activation. MeSADP is the principal agonist not only at P2Y1R, with a 10 times higher 
affinity reported at this receptor (human) than ADP (Waldo and Harden, 2004), but also 
at P2Y12-13, that are both expressed in astrocytes and coupled to Gi proteins (Von 
Kugelgen, 2006). In our study, the MeSADP actions have been demonstrated to be 
P2Y1R-mediated using the selective P2Y1R antagonist MRS2179 (10 M); in fact, 
MRS2179 doesn’t affect responses mediated by other P2Y receptors (Moro et al., 
1998), helping to identify P2Y1R-mediated responses (Von Kugelgen, 2006). 
In ADF cells MeSADP treatment, through the selective P2Y1R activation, didn’t induce 
any changes in A1R expression levels, thus showing on the contrary an increase in the 
  
selective A1R antagonist DPCPX affinity, towards A1R binding sites. Moreover, our re-
sults showed MeSADP induced a significant impairment of agonist-stimulated A1R-G 
protein coupling and A1R functional coupling to adenylyl cyclase; anyway, MeSADP 
didn’t result able to directly bind to A1R binding sites and to interfere with Gi pathway. 
In ADF cells, lines of evidence indicate the existence of an A1-P2Y1 receptor cross-talk 
and interaction at membrane level, thus suggesting a short-term heterologous P2Y1R-
mediated A1R desensitization. 
These data are partially in disagree with those reported by Yoshioka and co-workers 
(2001) which have demonstrated that the co-expression of A1 and P2Y1 receptors in-
duced a decrease both in A1R density and in A1R agonist/antagonist affinities and the 
P2Y1R agonist ADPβs resulted active in displacing [3H]NECA from A1R binding sites. 
Moreover, the agonist-stimulated A1R functional impairment at G protein coupling level 
was also reported in the A1R-P2Y1R co-transfected cell model by Yoshioka and co-
workers (2001) and resembled our previous data obtained in hippocampal rat mem-
branes (see Chapter 2). 
In ADF cells, indications about a A1R signalling pathway activation by the P2Y1R ago-
nist didn’t come out. In fact, the P2Y1R agonist MeSADP didn’t result able to directly 
bind to A1R binding sites either to activate Gi-cAMP pathway, as Yoshioka and co-
workers (2001) reported.  
Such a difference could be explained by considering that, in one side, our model is a na-
tive glial cell system, which expresses constitutively both the purinergic receptors, and, 
on the other side, we stimulated P2Y1Rs, while Yoshioka and co-workers worked in 
basal unstimulated conditions.  
In ADF cells the P2Y1 receptor activation increased A1R antagonist binding in one side 
but in the other side decreased agonist-stimulated A1R responsiveness. Therefore, ago-
nists and antagonists show different characteristics in ligand binding to GPCRs: while 
antagonists bind equally well to inactive receptor conformation (R) and to a spontane-
ously active form (R*), the agonists preferably bind to R* (Barrington et al., 1989; 
Lorenzen et al., 1996). Our results suggest TNF-alpha could induce a conformational 
change of A1R, thus reducing the A1R affinity for activation.  
Considering that ATP and P2Y1Rs have been reported to inhibit the release of glutamate 
(Mendoza-Fernandez et al., 2000; Koizumi et al., 2003; Rodrigues et al., 2005) and thus 
to interact in addition with A1Rs (Masino et al., 2002; Fredholm et al., 2003), we can 
  
speculate the A1-P2Y1 receptor interaction may be used to fine-tuning the purinergic 
signalling, thus leading in particular to the inhibition of neurotransmission (Nakata et 
al., 2004).  
Extracellular purines have been proposed to be an activity-dependent signalling mole-
cule that regulates glia-glia and glia-neuron communications (Franke et al., 2006). As-
troglial cells may play a far more active roll in neurotransmission than earlier believed 
(Anderson et al., 2003), thus contributing to damage or promoting neurogenesis and re-
generation in CNS. Moreover receptor cross-talk/heterodimerization may be a crucial 
event to understand biological systems involved in diseases pathogenesis and to develop 
strategical therapies nevertheless to set novel drug targets. Based on these considera-
tions, we envisage that the characterization of A1R cross-talk with P2Y1R in astroglial 
cells may have important functional implications. 
The functional role and the explanation for an A1-P2Y1 receptor cross-talk are compli-
cated by the availability of their endogenous ligands as well by the nucleotide different 
regulation in physiological or pathological conditions (Braun et al., 1998). 
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Chapter 4: 
Short-term TNF-alpha treatment induced A2B adenosine re-
ceptor desensitization in human astroglial cells 
 
 
 
4.1 Abstract 
Long-term glial cell treatment with the pro-inflammatory cytokine TNF-alpha has been 
demonstrated to increase the functional responsiveness of A2B adenosine receptors 
(A2BRs), which in turn synergize with the cytokine inducing chronic astrogliosis. In the 
present study, we investigated the short-term effects of TNF-alpha on A2BR functional 
responses in human astroglial cells (ADF), simulating the acute phase of cerebral dam-
age, which is characterized by cytokine and adenosine high level release. Short-term 
TNF-alpha cell treatment caused A2B AR phosphorylation inducing, in turn, impairment 
in A2BR-G protein coupling and cAMP production. These effects, which appeared to be 
maximal at 1000 U/ml TNF-alpha concentration for three hour cell exposure, were me-
diated by specific kinases such as PKA and PKC, but not by PI3K. The results could in-
dicate the A2BR functional impairment as a cell defense mechanism to counteract the 
A2B receptor-mediated effects during the acute phase of brain damage, underlying the 
A2BR as a possible target to modulate early inflammatory responses. 
 
 
4.2 Introduction 
Astrocytes, which are involved both in physiological brain functions and in pathological 
events (Eddleston and Mucke, 1993), are the most important source of extracellular 
adenine-based purines in the brain (Ciccarelli et al., 1999) and moreover express all the 
A1, A2A, A2B and A3 adenosine receptors (ARs) (Peakman and Hill, 1996; Trincavelli et 
al., 2002a, Trincavelli et al., 2004). Among all these receptors, A2BRs are quite unique, 
since they exhibit a relatively low affinity for adenosine and seem to be activated only 
under hypoxic or ischemic conditions, when large amounts of adenosine are released 
(micromolar range) (Ribeiro et al., 2003). Under these pathological conditions pro-
inflammatory cytokines, a group of potent multifunctional pleiotropic proteins, are re-
  
leased in the brain at high levels, contributing to neurodegeneration and inflammation 
processes (Szeleni, 2001; Zaremba et al., 2001). Evidence suggests a regulatory connec-
tion between inflammatory cytokines and the adenosine system: the former are known 
to be involved in ARs response regulation mechanisms (for A1R see Biber et al., 2001; 
for A2AR see Khoa et al., 2001; Trincavelli et al., 2002b; for A2BR see Rosi et al., 2003; 
Trincavelli et al., 2004), while ARs are involved in the regulation of the cytokine pro-
duction (for A2AR see Hasko et al., 2000; for A2BR see Zhang et al., 2005; Yang et al., 
2006). This reciprocal functional cross-talk between ARs and cytokines plays an impor-
tant role in the regulation of AR responses during pathological conditions. In particular, 
data from our group have demonstrated that human astroglial cell chronic exposure to 
TNF-alpha induces a delay in the A2BR desensitization process, causing up-regulation 
of the receptor functioning. Moreover, the A2BR, in association with TNF-alpha, medi-
ated chronic astrogliosis, thus suggesting this AR subtype could have a role in the long-
term control of astrocytic functions (Trincavelli et al., 2004). 
Following ischemia and trauma, TNF-alpha is quickly synthesized (2-6 hours) in the 
central nervous system by resident machrophages, astrocytes and microglia (Yu and 
Lau, 2000; Tehranian et al., 2002). Converging lines of evidence support the notion that 
the cytokine role in driving the short-term inflammatory response (Wang and Shuaib, 
2002). In this context, to understand how the cytokines regulate the functional respon-
siveness of adenosine neuromodulator systems in the acute phase of cerebral damage 
represents an important goal to develop new strategic therapeutic intervention. 
The aim of the present work was to investigate the A2BR modulation in ADF cells fol-
lowing short-term TNF-alpha exposure (3 hours) and to dissect the intracellular kinase 
pathways involved in TNF-alpha-mediated regulation of A2BR functioning. 
 
 
  
4.3 Materials and methods 
 
4.3.1 Materials 
[35S]GTPγS (specific activity 1250 Ci/mmol) was purchased from Amersham Biosci-
ences (Freiburg, Germany). ADA was from Roche Diagnostics GmbH (Mannheim, 
Germany). Cell culture media were from Cambrex Bio-Science (Verviers, Belgium). 
Electrophoresis reagents were purchased from Bio-Rad (Hercules, CA, USA).  
NECA and protease inhibitors were obtained from Sigma Chemical Co (St. Louis, MO, 
USA). MRS 1220 was purchased from Tocris Cookson (Bristol, United Kingdom) 
while SCH 58261 was a gift from Schoering-Plough. TNF-alpha (TNF-α) was pur-
chased from Li StarFish (Milan, Italy) and protein kinases inhibitors from Calbiochem 
(EMD Biosciences, affiliate of Merck KgaA, Darmstadt, Germany). 
Protein A SepharoseTM was from Amersham Pharmacia Biotech AB (Uppsala, Swe-
den). Anti-A2BR antibody (rabbit) was supplied by Alpha Diagnostic (San Antonio, TX, 
USA), while the anti-phosphothreonine antibody (rabbit) was from Chemicon Interna-
tional (Temecula, CA, USA). Anti-phospho-ERK ½ kinases antibody (mouse) and sec-
ondary antibodies (anti-rabbit and -mouse) were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). ECL Western blotting detection reagents were supplied 
by Amersham Biosciences (Freiburg, Germany).  
 
4.3.2 Cell culture and treatments 
ADF cells were grown adherently and maintained in culture in standard conditions, as 
previously described (pag. 62). 
For experiments, when the cells were grown to sub-confluence, the complete medium 
was replaced with fresh RPMI1640 or DMEM F-12 (only for cAMP assay) medium 
containing the different compounds for cell treatments. 
Aliquots of cells were treated without (Control) or with increasing TNF-alpha concen-
trations (10-1000 U/ml) for different times (5 min-12 hours) (TNF-α) at 37°C and then 
harvested for [35S]GTPγS assay, cAMP assay and immunoblotting analysis. 
Before being treated with TNF-alpha (1000 U/ml) for 3 hours, aliquots of cells were 
pre-incubated for 15 minutes with H89 dihydrochloride (1 µM) or Bisindolylmaleimide 
I (GF109203X) (1 µM) or wortmannin (500 nM) as inhibitors of Protein Kinase A 
(PKA), Protein Kinase C (PKC) or Phosphatidylinositol 3-Kinase (PI3K) respectively 
  
(Penn et al., 1999; Schulte and Fredholm, 2003; Nakanishi et al., 1992). Aliquots of 
cells were also pre-incubated with PKA and PKC inhibitors (1 µM) together. 
 
4.3.3 [35S]GTPγS Binding Assay on ADF cell membranes 
After different treatments, ADF cell membrane fractions were prepared and assayed ac-
cording to the method previously described (pag. 64) with minor modifications.  
A2BR coupling to G proteins was evaluated assessing the ability of the AR agonist 
NECA to stimulate [35S]GTPγS binding, in the presence of selective adenosine antago-
nists DPCPX, SCH 58261 and MRS 1220 to block A1, A2A and A3 receptors, respec-
tively. 
Briefly, after pre-incubation for 15’ at 30°C with ADA (2 U/ml), aliquots of membrane 
fractions (10 µg) were incubated for 60 minutes at 25°C in binding buffer A (25 mM 
Hepes, 100 mM NaCl, 5 mM MgCl2, EDTA 1 mM, pH 7,4 containing DTT 1 mM, 
BSA 0.1%) containing 5 µM GDP and 0.3-0.5 nM [35S]GTPγS. Cell membranes were 
stimulated with 1 µM NECA, in the presence of selective adenosine antagonists 
DPCPX, SCH 58261 and MRS 1220 (all used at 100 nM concentration). 
ADA was added to assay to eliminate the interference of endogenous adenosine in the 
basal [35S]GTPγS binding. Non-specific binding was determined in presence of 10 µM 
GTPγS and it resulted less than 10% of total binding. Binding reactions were terminated 
by rapid filtration under vacuum through Whatman GF/C glass fiber filters (Millipore 
Corporation): the filters were washed three times with 3 ml of binding buffer A and then 
counted in a scintillation cocktail. The concentration-dependent increase in specific 
[35S]GTPγS bindings by agonists was expressed as a percent increase above the basal 
unstimulated binding (fixed as 100%). All the experiments were performed in duplicate. 
For test-compounds dissolved in DMSO, the final solvent concentration never exceed 
2%. 
 
4.3.4 cAMP Assay on ADF cells 
Two days before the experiment, cells (50000 cells/well) were seeded in 24-well plate, 
to have sub-confluence conditions in 48 hours (105 cells/well). On the day of the cAMP 
assay, ADF cells were treated with or without TNF-alpha and protein kinases inhibitors 
and then placed in fresh DMEM F-12 medium with 2 U/ml ADA and 10 µM phos-
phodiesterases inhibitor Ro 201724 for 15 minutes at 37°C. Then NECA (1 µM)-
  
mediated cAMP production (incubated 15 min.), in presence of the A2A AR antagonist 
SCH 58261 (100 nM) (incubated 5 min. before NECA), was evaluated. Further, control 
experiments were performed stimulating cells in the presence of the selective A2BR an-
tagonist MRS 1706 (10 nM).  
The competitive cAMP enzyme immunoassay system kit (Sigma–Aldrich, St. Louis, 
MO, USA) was used, following the manufacture's instruction as previously described 
(pag. 65).  
 
4.3.5 A2BR Immunoprecipitation and Immunoblotting 
Control and TNF-alpha treated cells were processed by immunoblot following the 
method previously described (Chapter 3, pag. 65) with minor modifications. 
ADF cells, lysed in RIPA buffer and equalized by protein assay (1 mg proteins), were 
immunoprecipitated with anti-A2BR antibody (3 µg/sample) and Protein A Sepharose. 
Immune-complexes, after being resuspended in Laemmli solution and boiled for 5 min-
utes, were resolved by SDS-PAGE (12%), transferred to nitrocellulose membranes and 
treated overnight at 4°C with primary antibody against A2BR (1:1000: 1 µg/ml) or 
against phospho-threonine (1:500: 0.5 µg/ml). Membranes were then incubated with 
corresponding peroxidase-linked secondary antibody (rabbit), washed and developed 
using the ECL Western blotting detection reagents. Unspecific immunoprecipitation 
was assessed using non-immune rabbit IgG (3 µg, same amount of antibody). 
Stripping protocol was applied: after washing, nitrocellulose membranes were incubated 
in 100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7 (stripping buffer) 
at 50°C for 45 minutes. Membranes were then washed two times and incubation with a 
different primary antibody started.  
Western blot band intensity was quantified by densitometric scanning and by a gel 
documentation system (ImageJ Program, National Institutes of Health, USA). Phospho-
threonine immunoreactive bands were normalized by corresponding A2BR immunoreac-
tive bands and represented as arbitrary units (optical density, OD). 
For ERK ½ kinase study, Control and TNF-alpha (1000 U/ml, 3 hours)-treated ADF 
cells were stimulated with 100 nM NECA for different times (0-60 min) or with differ-
ent NECA concentrations (10nM-1µM) for 15 min. The ERK ½ kinase phosphorylation 
was assayed on cell lysates by immunoblotting, with the specific antibody recognizing 
the dually phosphorylated p-42 and p-44 kDa MAP kinases (1:500: 0.4 µg/ml). 
  
4.3.6 Data analysis 
Agonist dose–response curves were analyzed by the non-linear regression curve-fitting 
computer program GraphPad PRISM Version 4.00 (GraphPad Software, San Diego, 
CA, USA) and the EC50 values were derived. All data are reported as mean±SEM of 
three different experiments (at least) performed in duplicate. All data were statistically 
analyzed with One-Way ANOVA (Tukey's multiple comparison test) by the GraphPad 
PRISM. Significance refers to results where P <0.05 was obtained. 
 
 
 
 
4.4 Results 
 
4.4.1 A2B R-G protein coupling in control and short-term TNF-alpha treated cells 
As a first step, we investigated the effect of short-term TNF-alpha cell exposure on the 
A2BR-G protein coupling efficacy. In time dependence experiments, we demonstrated 
TNF-alpha cell treatment induced a time-dependent decrease in A2BR-G protein cou-
pling (Fig. 1A), with a maximal effect after 3 hour incubation (# P<0.01 TNF-alpha 3 
hours vs. Control). Moreover, following 3 hours cell exposure, the TNF-alpha-mediated 
impairment of receptor-G protein activation occurred in a concentration dependent man-
ner (Fig. 1B). TNF-alpha cell treatments did not induce any significant change in the 
basal [35S]GTPγS binding (data not shown), thus demonstrating no effects on the G pro-
tein functional state. 
 
  
 
 
Fig. 1: TNF-alpha-mediated regulation of the A2BR-G protein coupling: 
time (A) and concentration (B) dependence. The ability of 1 µM NECA 
(in the presence of A1, A2A and A3 antagonists) to stimulate [35S]GTPγS 
binding was evaluated in ADF cell membranes, following cell treatment 
without or with 1000U/ml TNF-alpha for different times (5 min-12 
hours, A) or following cell treatment with different TNF-alpha concen-
trations (10-1000 U/ml) for 3 hours (B). Data, reported as mean±SEM 
(n=5), are expressed as percentage of basal specific [35S]GTPγS binding, 
set to 100%. 
 
To dissect the possible intracellular pathways involved in the TNF-alpha mediated A2BR 
regulation, the effect of the selective PKA, PKC and PI3K inhibitors on A2BR-G protein 
coupling was assessed (Fig. 2).  
  
 
 
Fig. 2: Effects of intracellular kinase inhibitors on the TNF-alpha medi-
ated A2BR-G protein uncoupling. ADF cells were pre-incubated without 
or with PKA inhibitor (H89, 1 µM) or PKC inhibitor (GF109203X, 1 
µM) or PI3K inhibitor (Wortmannin, 500 nM) or PKA and PKC inhibi-
tors (1 µM) together, for 15 min. Cells were then treated with or without 
TNF-alpha 1000 U/ml for 3 hours and then the ability of 1 µM NECA 
(in the presence of A1, A2A and A3 antagonists) to stimulate [35S]GTPγS 
binding was assessed. Data, reported as mean±SEM (n=5), are expressed 
as percentage of basal specific [35S]GTPγS binding, set to 100%. 
# P<0.01 vs. Control; ** P<0.01 and *** P<0.001 vs. TNF-alpha (One-
way ANOVA). 
 
 
Cell pre-exposure to the PKA or PKC inhibitor was able to counteract TNF-alpha (1000 
U/ml for 3 hours) effects, by inducing a partial recovery in the agonist effectiveness in 
stimulating GTPγS binding (** P<0.01 TNF-alpha+PKA inhibitor or TNF-alpha+PKC 
inhibitor vs. TNF-alpha alone). Moreover, the simultaneous cell pre-incubation with the 
PKA and PKC inhibitors completely restored the A2BR/G protein coupling efficacy up 
to control level (*** P<0.001 TNF-alpha+PKA and PKC inhibitors vs. TNF-alpha 
  
alone; P>0.05 TNF-alpha+PKA and PKC inhibitors vs. Control; Fig. 2). These data 
suggested both PKA and PKC intracellular kinases were involved in the TNF-alpha 
mediated regulation of A2BR-G protein coupling. 
 
 
4.4.2 A2BR functional responsiveness in control and short-term TNF-alpha treated 
cells  
As a second step, we evaluated the time and concentration dependence of TNF-alpha 
effects on the A2BR functional responsiveness. The A2BR responsiveness was quantified 
evaluating the ability of the agonist NECA, in presence of the A2AR antagonist SCH 
58261 (100 nM), to stimulate intracellular cAMP production in control and treated cells 
(Trincavelli et al., 2004). Cell pre-incubation with TNF-alpha (1000  U/ml) for different 
times induced a significant decrease in the A2BR functional responsiveness (Fig. 3A), 
with a maximal effect following 3 hours incubation (# P<0.01 TNF-alpha 3 hours vs. 
Control). The TNF-alpha mediated impairment of A2BR response occurred in a concen-
tration dependent manner, with a maximal effect at 1000 U/ml cytokine following 3 
hours treatment (Fig. 3B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 3: TNF-alpha effect on the A2BR-mediated cAMP accumulation: 
time (A) and concentration dependence (B). The ability of 1 µM NECA 
(in the presence of 100 nM SCH 58261) to stimulate cAMP accumula-
tion was evaluated in ADF cells following cell treatment without or with 
1000U/ml TNF-alpha for different times (15 min-12 hours, A) or follow-
ing cell treatment with different TNF-alpha concentrations (10-1000 
U/ml) for 3 hours (B). Data, reported as mean±SEM (n=3), are expressed 
as cAMP levels (pmol/105 cells). 
 
 
  
Moreover, the effect of the PKA, PKC and PI3K inhibitors on the short-term TNF-
alpha-mediated A2BR desensitization was assessed. Data in Fig. 4 showed that cell pre-
incubation with PKA or PKC inhibitors counteracted the TNF-alpha effects, with a 75.0 
% and 67.3 % recovery of the agonist-mediated-mediated cAMP accumulation, respec-
tively (P<0.01 TNF-alpha+PKA inhibitor and TNF-alpha+PKC inhibitor vs. TNF-alpha 
alone). The cell pre-exposure to PKA and PKC inhibitors together induced a nearly 
complete recovery of the A2BR functional responsiveness (P>0.05 TNF-alpha+PKA and 
PKC inhibitors vs. Control). On the contrary, PI3K inhibitor was not able to restore the 
A2BR functional responsiveness at level of second messenger system (P>0.05 TNF-
alpha+ PI3K inhibitor vs. TNF-alpha alone). 
 
 
 
Fig. 4: Effects of intracellular kinase inhibitors on the TNF-alpha-
mediated A2BR desensitization. ADF cells were pre-incubated without or 
with PKA inhibitor (H89, 1 µM), PKC inhibitor (GF109203X, 1 µM), 
PI3K inhibitor (Wortmannin, 500 nM) or PKA and PKC inhibitors (1 
µM) together, for 15 min. Cells were then treated with or without TNF-
alpha 1000 U/ml for 3 hours and the ability of 1 µM NECA (in the pres-
ence of 100 nM SCH 58261) to stimulate cAMP accumulation was 
  
evaluated. Data, reported as mean±SEM (n=3), are expressed as cAMP 
(pmol/105 cells). 
# P<0.01 vs. Control; * P<0.05, ** P<0.01 and *** P<0.001 vs. TNF-
alpha (One-way ANOVA). 
 
 
4.4.3 A2B R expression and phosphorylation levels in control and short-term TNF-
alpha treated cells 
To investigate the molecular mechanisms involved in the TNF-alpha mediated  A2BR 
desensitization, A2B receptor expression and phosphorylation levels were evaluated fol-
lowing 1000 U/ml cytokine cell treatment; in particular, we focused on the phosphoryla-
tion status of threonine residues, which are primarily involved in GPCR receptor desen-
sitization (Palmer and Stiles, 2000; Ferguson, 2001). 
As a first step, we investigated the TNF-alpha time-dependent effects on A2BR protein 
expression and threonine-phosphorylation levels (Fig. 5A-B). ADF cells were treated 
with medium alone or with TNF-alpha (1000 U/ml) for different times and then A2BR 
was immunoprecipitated using an antibody against A2BR and processed by immunoblot-
ting assay: the immunoprecipitates were resolved by SDS electrophoresis, transferred to 
nitrocellulose membranes and probed before with the anti-A2BR antibody and then with 
the anti-phosphothreonine antibody. The A2BR expression levels were not affected by 
the different time TNF-alpha treatments (data not shown), in agreement with data al-
ready published (Trincavelli et al., 2004). On the contrary, TNF-alpha induced a time-
dependent increase in the basal A2BR phosphorylation levels, with a maximal effect fol-
lowing 3 hour cell exposure (P<0.01 all columns vs. TNF-alpha 3hours; Fig. 5B). These 
results suggest that TNF-alpha induced A2BR desensitization: thus the cytokine affected 
the receptor regulatory processes by increasing the basal receptor phosphorylation.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 5: TNF-alpha time-dependent effects on the A2BR threonine-
phosphorylation levels. A) ADF cells were treated with medium alone 
(Control) or with TNF-alpha (1000 U/ml) for different time (1 hour; 3 
hours; 24 hours). Cells were then lysed and an amount of 1 mg of pro-
teins was immunoprecipitated using a polyclonal antibody against A2BR. 
The immunoprecipitates were probed with an anti-phosphothreonine an-
tibody to detect the threonine receptor phosphorylation levels. Phospho-
threonine immunoreactive bands (at around 44 kDa) were quantified by 
densitometric scanning and normalized by the corresponding A2BR im-
munoreactive bands. B) Graph bar represents the normalized data 
(mean±SEM; n=3) obtained by the densitometric scanning of immunore-
active bands normalized by corresponding A2BR immunoreactive bands.  
** P<0.01 all columns vs. TNF-alpha 3hours (One-way ANOVA). 
 
 
 
 
  
As shown in Fig. 6, the TNF-alpha-mediated A2BR phosphorylation was significantly 
prevented by the PKA (optical density= 0.4±0.19; P<0.01 vs. TNF-alpha alone) and 
PKC (optical density= 0.52±0.11; P<0.01 vs. TNF-alpha alone) inhibitors, whereas 
PI3K did not seem to be involved in the regulation of receptor phosphorylation (optical 
density= 1.21±0.11; P>0.05 vs. TNF-alpha alone). Cell pre-incubation with PKA and 
PKC inhibitors together induced a nearly complete inhibition of the TNF-alpha-
mediated A2BR phosphorylation (optical density= 0.46±0.08; P>0.05 vs. Control and 
P<0.01 vs. TNF-alpha alone). Moreover, A2B AR expression levels were not affected by 
the different protein kinase inhibitor treatments (data not shown). 
 
 
Fig. 6: Effects of intracellular kinase inhibitors on the TNF-alpha medi-
ated A2BR threonine-phosphorylation levels. Cells were pretreated with-
out or with PKC inhibitor (GF109203X, 1 µM) or PKA inhibitor (H89, 1 
  
µM) or PI3K inhibitor (Wortmannin, 500 nM) or PKA and PKC inhibi-
tors (1 µM) together for 15 min and then stimulated with TNF-alpha 
(1000U/ml) for 3 hours. A) The immunoprecipitate samples, after being 
probed with the anti-A2BR antibody, were subjected to analysis with the 
anti-phosphothreonine antibody to detect the extent of threonine receptor 
phosphorylation levels. B) Graph bar represents the normalized data 
(mean±SEM; n=3) of the phospho-threonine immunoreactive bands 
quantified by densitometric scanning and normalized by the correspond-
ing A2BR immunoreactive bands. # P<0.01 vs. Control; ** P<0.01 vs. 
TNF-alpha (One-way ANOVA). 
 
 
4.4.4 A2B AR-mediated ERK ½ phosphorylation in control and short-term TNF-alpha 
treated cells 
In order to investigate whether the impairment of A2BR responsiveness, induced by 
short-term TNF-alpha exposure, could induce any significant changes in the A2BR-
activated intracellular phosphorylative pathways, we evaluated the effect of 1000 U/ml 
TNF-alpha for 3 hours on the A2BR-mediated ERK ½ phosphorylation.  
Data obtained from the immunoblotting assays demonstrated that, in Control cells, the 
agonist NECA (100 nM) induced an ERK ½ phosphorylation with a transient and mo-
nophasic kinetics and a maximal effect following 15 minutes (Fig. 7A). Moreover, the 
ERK ½ activation occurred in a concentration dependent manner, with a maximal re-
sponse at nanomolar NECA concentration (Fig. 7B).  
When ADF cells were pre-incubated with TNF-alpha (1000 U/ml) for 3 hours, a signifi-
cant decrease in the maximal NECA A2BR-mediated ERK ½ phosphorylation was de-
tected, thus suggesting the cytokine impaired the A2BR-mediated intracellular phos-
phorylative pathways (* P<0.05 Control 15’ vs. TNF-alpha 15’, One-way ANOVA) 
(Fig. 7A). On the contrary, no significantly changes were induced on kinetic ERK ½ ac-
tivation, mediated by A2BRs, following cytokine treatment (Fig. 7B). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig. 7: TNF-alpha maximal effects on the A2BR-mediated ERK ½ phos-
phorylation: time (A) and concentration (B) dependence. ADF cells, pre-
treated with medium alone (Control,  black) or with 1000 U/ml TNF-α 
(▲, grey) for 3 hours, were stimulated with 100 nM NECA for different 
times (0-60 min, A) or with different NECA concentrations (10nM-
1µM) for 15 min (B). The ERK ½ kinase phosphorylation level was de-
termined by immunoblotting with an antibody recognizing the dually 
phosphorylated p-42 and p-44 kDa MAP kinases. The immunoreactivity 
  
was quantified by densitometry and data were normalized against the 
basal phosphorylation level (set to 1). Data are expressed as mean±SEM 
(n=3). 
* P<0.05 TNF-α 15’ vs. Control 15’ (One-way ANOVA). 
 
 
 
4.5 Discussion 
The presence and the selective functional responsiveness of A2BRs in ADF cells had 
been previously characterized and demonstrated in ADF cells (Trincavelli et al., 2004). 
Furthermore it had been also assayed that all NECA-stimulated responses, in the pres-
ence of A1-2A-3R antagonists, were abolished by the cell pre-incubation with the selec-
tive A2BR antagonist MRS 1706; so these responses were mediated by A2BR subtype in 
ADF cells. 
The ADF cell short-term exposure to the pro-inflammatory cytokine TNF-alpha induced 
impairment of the A2BR responsiveness, causing, in particular, a reduction of the agonist 
effectiveness in promoting the receptor-G protein coupling and in stimulating the ade-
nylyl cyclase pathway as well the intracellular phosphorylative ERK ½ pathways, with 
a maximal effect following 3 hour cytokine incubation. These effects appeared to be 
also associated with an increase in the receptor basal phosphorylation levels, which may 
be responsible for the observed functional effects. These results suggested TNF-alpha 
was able to induce a short-term A2BR desensitization.  
Because of GPCR functional alterations could be ascribed to changes of intracellular 
signalling proteins involved in heterologous and/or homologous GPCR regulations, in-
cluding different protein kinases (Vazquez-Prado et al., 2003), we investigated the 
PKA, PKC and PI3K involvement in the TNF-alpha mediated effects on A2BRs. All 
these kinases, besides representing a converging point for different intracellular phos-
phorylative pathways, are activated both by the cytokine TNF-alpha and by A2BRs 
(Linden et al., 1999; Baud and Karin 2001; MacEwan et al., 2002; Zhang et al., 2002; 
Queiroz et al., 2004). Moreover, several data suggest a role for these proteins in the 
feed-back regulation of several GPCRs through different mechanisms, such as a direct 
effect on the receptor itself and/or an effect on the G protein activity (Casas-Gonzalez et 
al., 2000; Jo et al., 2002; Tan et al., 2003). Among these protein kinases, while PI3K 
didn’t result to be involved in the TNF-alpha mediated A2BR regulation, PKA and PKC 
  
mediated the TNF-alpha effects on A2BR phosphorylation, receptor G protein uncou-
pling and impairment in adenylyl cyclase pathway.  
In line with our findings, it has been recently demonstrated that cytokines regulate the 
β2 adrenergic receptor responsiveness via PKA pathway through the modulation of dif-
ferent targets including the receptor itself, adenylyl cyclase (Guo et al., 2005) and Gs 
protein expression (Chapman et al., 2005); these data suggest cytokines may modulate 
the GPCR functioning by acting both at receptor and at downstream signalling level. In 
a similar way, PKC has been involved in the control of the β adrenergic receptor func-
tioning through receptor phosphorylation, Gs expression and intracellular phosphoryla-
tion regulation (Levesque and Crooke, 1998). In our system, TNF-alpha did not appear 
to modify either G protein activation state or basal adenylyl cyclase activity: its effects 
mainly occurred at A2B receptor level. This difference could be justified by the different 
time of cytokine cell exposure: in fact TNF-alpha effects at the level of downstream 
signalling have been detected following long-term cell treatment. IFN gamma, for ex-
ample, has been demonstrated to regulate A2BR functional responses by affecting the 
adenylyl cyclase activity following 12 hours cell treatment (Kolachala et al., 2005). In 
summary PKA and PKC, which represent the intracellular pathways involved in AR-
mediated control of the cytokine production, are, in turn, involved in the control of the 
A2B receptor responses in the acute phase of TNF-alpha release.  
Comparing the present data with those previously published by our laboratory, a signifi-
cant increase in the A2BR functional responses was detected when TNF-alpha cell 
treatment was prolonged up to 24 hours (Trincavelli et al., 2004): it might be suggested 
a dualistic and opposite effect of TNF-alpha on the A2BR functioning after short- and 
long-term cytokine cell exposure. These data parallel with those obtained in astroglioma 
(Fredholm and Altiok, 1994) and endothelial cells (Nguyen et al., 2003), thus demon-
strating the A2BR-mediated effects are differently modified in a time dependent manner 
by inflammatory mediators and underlying the AR system as a promising target to 
modulate cerebral damage progression. 
In response to injuries, resident CNS cells generate pro-inflammatory cytokines, which 
may contribute to acute and chronic brain disease pathogenesis through the recruitment 
of immune cells and the activation of glial cells (for review see Lucas et al., 2006). 
However, cytokines may display a dualistic role, with detrimental acute effects but also 
beneficial effects in long-term repair and recovery. In particular, TNF-alpha, synthe-
sized by macrophages, astrocytes and microglia with a rapid kinetic following cerebral 
  
trauma or ischemia (up to 2 hours; Yu and Lau, 2000; Yin et al., 2003; Vitarbo et al., 
2004), has been demonstrated to be pro-inflammatory during the acute phase of the in-
flammatory response and immunosuppressive during the chronic phase (Wang and 
Shuaib, 2002).  
Zhong et al. (2005) have showed a synergic effect between A2BRs and hypoxia in acti-
vating human lung fibroblasts, thus suggesting the adenosine system/inflammatory me-
diator interaction as a common mechanism in both central and peripheral tissues. In par-
ticular in astroglial cells, a bi-directional functional cross-talk between cytokines and 
A2BR adenosine system has been described as an important mechanism to regulate the 
cerebral damage progression (Fredholm and Altiok, 1994; Rosi et al., 2003; Trincavelli 
et al., 2004). 
The A2BR has been implicated both in the stimulation (Feoktistov et al., 2002; Zhong et 
al., 2004; Zhang et al., 2005) and inhibition (Kreckler et al., 2006; Yang et al., 2006) of 
cytokine release, which in turn can exacerbate or reduce inflammatory processes. More-
over inflammatory signals other than TNF-alpha have been shown to regulate A2BR sig-
nalling: for example LPS (Nemeth et al., 2003) and IFN-γ (Xaus et al., 1999), which 
was recently shown to elevate A2B receptor expression in macrophages. 
Since the A2BR results involved in inflammatory processes, even if with a still enig-
matic role (Linden, 2006), the TNF-alpha-mediated activity reduction of A2BR may rep-
resent a potential feed-back mechanism to control the inflammatory effects induced by 
neurotoxic compounds and pro-inflammatory cytokines, released in the acute phase of 
brain damage. On the contrary, in the chronic phase of brain injury, TNF-alpha, by a 
significant up-regulation of A2BR responsiveness, contributes to the reactive astrogliosis 
(Trincavelli et al., 2004), thus suggesting A2BRs as a novel target for neuroinflamma-
tory-neurodegenerative diseases. 
 
 
 
 
 
 
 
 
 
  
4.6 References 
• Baud V and Karin M (2001) Signal transduction by tumor necrosis factor and its 
relatives. Trends Cell Biol 11:372–377. 
• Biber K, Lubrich B, Fiebich BL, Boddeke HW and van Calker D (2001) Inter-
leukin-6 enhances expression of adenosine A(1) receptor mRNA and signaling 
in cultured rat cortical astrocytes and brain slices. Neuropsychopharmacology 
24:86-96.  
• Casas-Gonzalez P, Vazquez-Prado J and Garcia-Sainz JA (2000) Lysophos-
phatidic acid modulates alpha(1b)-adrenoreceptor phosphorylation and function: 
roles of Gi and phosphoinositide 3-kinase. Mol Pharmacol 57:1027-1033.  
• Chapman NR, Smyrnias I, Anumba DO, Europe-Finner GN and Robson SC 
(2005) Expression of the GTP-binding protein (Galphas) is repressed by the nu-
clear factor kappaB RelA subunit in human myometrium. Endocrinology 
146:4994-5002.  
• Ciccarelli R, Di Iorio P, Giuliani P, D'Alimonte I, Ballerini P, Caciagli F and 
Rathbone MP (1999) Rat cultured astrocytes release guanine-based purines in 
basal conditions and after hypoxia/hypoglycemia. Glia 25:93-98.  
• Eddleston M and Mucke L (1993) Molecular profile of reactive astrocytes im-
plications for their role in neurologic disease. Neurosci 54, 15-36. 
• Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Voyno- Yasene-
tskaya T and Biaggioni I (2002) Differential expression of adenosine receptors 
in human endothelial cells: role of A2B receptors in angiogenic factor regula-
tion. Circ Res 90:531-538.  
• Ferguson SS (2001) Evolving concepts in G protein-coupled receptor endocyto-
sis: the role in receptor desensitisation and signaling. Pharmacol Rev 53:1-24. 
• Fredholm BB and Altiok N (1994) Adenosine A2B receptor signalling is altered 
by stimulation of bradykinin or interleukin receptors in astroglioma cells. Neu-
rochem Int 25:99-102.  
• Guo M, Pascual RM, Wang S, Fontana MF, Valancius CA, Panettieri RA Jr, 
Tilley SL and Penn RB (2005) Cytokines regulate beta-2-adrenergic receptor re-
sponsiveness in airway smooth muscle via multiple PKA-and EP2 receptor-
dependent mechanisms. Biochemistry 44:13771-13782.  
  
• Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Mar-
ton A and Szabo C (2000) Adenosine inhibits IL-12 and TNF-α production via 
A2A adenosine receptor dependent and independent mechanism. Faseb J 
14:2065-2074. 
• Jo SH, Leblais V, Wang PH, Crow MT and Xiao RP (2002) Phosphatidylinosi-
tol 3-kinase functionally compartmentalizes the concurrent Gs signaling during 
beta2-adrenergic stimulation. Circ Res 91:46-53.  
• Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N and Cronstein 
BN (2001) Inflammatory cytokines regulate function and expression of adeno-
sine A2A receptors in human monocytic THP-1 cells. J Immunol 167:4026-
4032.  
• Kolachala V, Asamoah V, Wang L, Srinivasan S, Merlin D and Sitaraman SV 
(2005) Interferongamma down-regulates adenosine 2b receptor- mediated sig-
naling and short circuit current in the intestinal epithelia by inhibiting the ex-
pression of adenylate cyclase. J Biol Chem 280:4048-4057.  
• Kreckler LM, Wan TC, Ge ZD and Auchampach JA (2006) Adenosine inhibits 
tumor necrosis factor-alpha release from mouse peritoneal macrophages via 
A2A and A2B but not the A3 adenosine receptor. J Pharmacol Exp Ther 
317:172-180.  
• Levesque L and Crooke ST (1998) Depletion of protein kinase C-alpha by an-
tisense oligonucleotides alters beta-adrenergic function and reverses the phorbol 
ester-induced reduction of isoproterenol-induced adenosine 3'-5'-cyclic mono-
phosphate accumulation in murine Swiss 3T3 fibroblasts. J Pharmacol Exp Ther 
287:425-434.  
• Linden J (2006) New insights into the regulation of inflammation by adenosine. 
J Clin Invest. 116:1835-1837.  
• Linden J, Thai T, Figler H, Jin X and Robeva A (1999) Characterization of hu-
man A2b adenosine receptors: radioligand binding, western blotting and cou-
pling to Gq in human embryonic kidney 293 cells and HMC-1 mast cells. Mol 
Pharmacol 56:705-713.  
• Lucas SM, Rothwell NJ and Gibson RM (2006) The role of inflammation in 
CNS injury and disease. Br J Pharmacol 147:S232-240.  
  
• MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular 
consequences. Cell Signal 14:477-492.  
• Nakanishi S, Kakita S, Takahashi I, Kawahara K, Tsukuda E, Sano T, Yamada 
K, Yoshida M, Kase H and Matsuda Y (1992) Wortmannin, a microbial product 
inhibitor of myosin light chain kinase. J Biol Chem 267:2157-2163.  
• Nemeth ZH, Leibovich SJ, Deitch EA, Vizi ES, Szabo C, Hasko G (2003) 
cDNA microarray analysis reveals a nuclear factor-kappaB-independent regula-
tion of macrophage function by adenosine. J Pharmacol Exp Ther. 306:1042-
1049.  
• Nguyen DK, Montesinos MC, Williams AJ, Kelly M and Cronstein BN (2003) 
Th1 cytokines regulate adenosine receptors and their downstream signalling 
elements in human microvascular endothelial cells. J Immunol 171:3991-3998.  
• Palmer TM and Stiles GL (2000) Identification of threonine residues controlling 
the agonist-dependent phosphorylation and desensitization of the rat A(3) 
adenosine receptor. Mol Pharmacol. 57:539-545. 
• Peakman MC and Hill SJ (1996) Adenosine A1 receptor-mediated inhibition of 
cyclic AMP accumulation in type-2 but not type-1 rat astrocytes. Eur J Pharma-
col 306:281-289.  
• Penn RB, Parent JL, Pronin AN, Panettieri RA Jr and Benovic JL (1999) Phar-
macological inhibition of protein kinases in intact cells: antagonism of beta 
adrenergic receptor ligand binding by H-89 reveals limitations of usefulness. J 
Pharmacol Exp Ther 288:428-437.  
• Queiroz G, Quintas C, Talaia C, Goncalves J 2004 Coupling to protein kinases 
A and C of adenosine A2B receptors involved in the facilitation of noradrenaline 
release in the prostatic portino of rat vas deferens. Neuropharmacol 47: 216-224. 
• Ribeiro JA, Sebastiao AM and de Mendonca A (2003) Participation of adeno-
sine receptors in neuroprotection. Drug News Perspect 16:80-86.  
• Rosi S, McGann K, Hauss-Wegrzyniak B, Wenk GL (2003) The influence of 
brain inflammation upon neuronal adenosine A2b receptors. J Neurochem 
86:220-227. 
• Schulte G and Fredholm BB (2003) The GS-coupled adenosine A2B receptor 
recruits divergent pathways to regulate ERK1/2 and p38. Exp Cell Research 
290:168-176. 
  
• Sitaraman SV, Wang L, Wong M, Bruewer M, Hobert M, Yun CH, Merlin D 
and Madara JL (2002) The adenosine 2b receptor is recruited to the plasma 
membrane and associates with E3KARP and Ezrin upon agonist stimulation. J 
Biol Chem 277:33188-33195. 
• Szelenyi J (2001) Cytokines and the central nervous system. Brain Res Bull 
54:329-338.  
• Tan M, Groszer M, Tan AM, Pandya A, Liu X and Xie CW (2003) Phospho-
inositide 3-kinase cascade facilitates mu-opioid desensitization in sensory neu-
rons by altering G-proteineffector interactions. J Neurosci 23:10292-10301.  
• Tehranian R, Andell-Jonsson S, Beni SM, Yatsiv I, Shohami E, Bartfai T, 
Lundkvist J and Iverfeldt K (2002) Improved recovery and delayed cytokine in-
duction after closed head injury in mice with central overexpression of the se-
creted isoform of the interleukin-1 receptor antagonist. J Neurotrauma 19:939-
951.  
• Trincavelli ML, Costa B, Tuscano D, Lucacchini A and Martini C (2002b) Up-
regulation of A(2A) adenosine receptors by proinflammatory cytokines in rat 
PC12 cells. Biochem Pharmacol 64:625-631.  
• Trincavelli ML, Marroni M, Tuscano D, Ceruti S, Mazzola M, Mitro N, Ab-
bracchio MP and Martini C (2004) Regulation of A2B adenosine receptor func-
tioning by tumor necrosis factor a in human astroglial cells. J Neurochem 
91:1180-1190.  
• Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, Ab-
bracchio MP, Jacobson KA, Cattabeni F and Martini C (2002a) A3 adenosine 
receptors in human astrocytoma cells: agonist-mediated desensitisation, inter-
nalization, and down-regulation. Mol Pharmacol 62:1373-1384.  
• Vazquez-Prado J, Casas-Gonzalez P, Garcia-Sainz AJ (2003) G protein-coupled 
receptor cross-talk: pivotal roles of protein phosphorylation and protein-protein 
interactions. Cell Signal 15:549-557. 
• Vitarbo EA, Chatzipanteli K, Kinoshita K, Truettner JS, Alonso OF and Dietrich 
WD (2004) Tumor necrosis factor alpha expression and protein levels after fluid 
percussion injury in rats: the effect of injury severity and brain temperature. 
Neurosurgery 55:416-424.  
  
• Wang CX and Shuaib A (2002) Involvement of inflammatory cytokines in cen-
tral nervous system injury. Prog Neurobiol 67:161-172.  
• Xaus J, Valledor AF, Cardo M, Marques L, Beleta J, Palacios JM, Celada A 
(1999) Adenosine inhibits macrophage colony-stimulating factor-dependent pro-
liferation of macrophages through the induction of p27kip-1 expression. J Im-
munol. 163:4140-4149.  
• Yang D, Zhang Y, Nguyen HG, Koupenova M, Chauhan AK, Makitalo M, 
Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, 
Gavras H, Wagner DD and Ravid K (2006) The A2B adenosine receptor pro-
tects against inflammation and excessive vascular adhesion. J Clin Invest 
116:1913-1923.  
• Yin L, Ohtaki H, Nakamachi T, Dohi K, Iwai Y, Funahashi H, Makino R and 
Shioda S (2003) Expression of tumor necrosis factor alpha (TNFalpha) follow-
ing transient cerebral ischemia. Acta Neurochir Suppl 86:93-96.  
• Yu AC and Lau LT (2000) Expression of interleukin-1 alpha, tumor necrosis 
factor alpha and interleukin-6 genes in astrocytes under ischemic injury. Neuro-
chem Int 36:369-377.  
• Zaremba J, Skrobanski P and Losy J (2001) Tumour necrosis factor-alpha is in-
creased in the cerebrospinal fluid and serum of ischemic stroke patients and cor-
relates with the volume of evolving brain infarct. Biomed Pharmacother 55:258-
263.  
• Zhang JG, Hepburn L, Cruz G, Borman RA and Clark KL (2005) The role of 
adenosine A2A and A2B receptors in the regulation of TNF-alpha production by 
human monocytes. Biochem Pharmacol 69:883-889.  
• Zhang JM, Li H, Liu B and Brull SJ (2002) Acute topical application of tumor 
necrosis factor a evokes protein kinase A-dependent responses in rat sensory 
neurons. J Neurophysiol 88:1387-1392.  
• Zhong H, Belardinelli L, Maa T and Zeng D (2005) Synergy between A2B 
adenosine receptors and hypoxia in activating human lung fibroblasts. Am J 
Respir Cell Mol Biol 32:2-8.  
• Zhong H, Belardinelli L, Maa T, Feoktistov I, Biaggioni I and Zeng D (2004) 
A2B adenosine receptors increase cytokine release by bronchial smooth muscle 
cells. Am J Respir Cell Mol Biol 30:118-125. 
  
 
  
Charter 5: 
General conclusions 
 
 
5.1 Conclusions  
 
5.1.1 A1R-P2Y1R 
In the present work, we investigated the localization/co-localization of purinergic A1 
and P2Y1 receptors and subsequently their functional interactions, both in rat hippo-
campus, which is considered as a damage sensitive brain area, and in human astroglial 
cells, which are important in CNS maintenance and damage progression.  
The results have demonstrated: 
 
• There is a significantly high expression of both A1 and P2Y1 receptors on synap-
tic and astroglia membranes in hippocampus. The receptors showed also a func-
tional interaction at membrane G protein level: P2Y1R activation induced an im-
pairment of A1R-G protein coupling, while A1R activation increased the P2Y1R 
functional coupling to G protein. 
• In ADF astroglial cells, the P2Y1R activation by its agonist MeSADP induced an 
increase of A1R antagonist affinity, an impairment of A1R-G protein coupling 
and a decrease of A1R-stimulated adenylate cyclase activity, thus suggesting a 
heterologous A1R desensitisation induced by the P2Y1R activation. 
 
A1 and P2Y1 receptors cellular co-localization, interaction and functional heterodimeri-
zation may help to clarify the patho-physiological functions of ATP and adenosine in 
CNS, regarding the possible alterations of P1-P2 receptor regulation processes during 
pathological conditions. 
 
 
 
 
 
  
5.1.2 A2BR-cytokine 
For cytokines, equally immunoregulators and modulators of neural functions, a bidirec-
tional interaction with CNS neurotrasmitters has been proposed, because cytokines can 
modulate the action and survival of neuronal and glial cells but their production is con-
trolled just by neurotrasmitters, produced by those cells (Szelenyi, 2001). 
In the present work we investigated the functional cross-talk between the inflammatory 
cytokine TNF-α, in human astroglial cells and A2B receptors.  
The results have demonstrated: 
 
• ADF cell preincubation with TNF-α induced a significant concentration and 
time-dependent decrease of A2BR-mediated responsiveness, with a maximal ef-
fect following 3 hours incubation; moreover, the impairment of A2BR function-
ing occurred in a concentration dependent manner, with a maximal effect at 
1000 U/ml cytokine concentration. Moreover TNF-α did not induce any signifi-
cant changes in A2B receptor levels. 
• Short-term (3 hours) ADF cell exposure to TNF-α induced A2BR responsiveness 
impairment, in particular reduction in the efficacy of the adenosine agonist to 
promote receptor-G protein coupling, to stimulate adenylyl cyclase pathway and 
to activate ERK ½ phosphorylation. These effects, associated with an increase in 
the basal receptor phosphorylation levels which may be responsible for the func-
tional effects, resulted mediated by the intracellular kinase PKA and PKC. 
 
A main finding of the present work is that the proinflammatory cytokine TNF-α selec-
tively modulated A2BRs responsiveness in human ADF cells. Results confirm that shed-
ding light on adenosine receptor-cytokine cross-talk might be a useful tool to clarify the 
patho-physiological role of A2BR in response to brain damage. 
 
 
5.2 Future perspectives 
In the CNS the metabolic stress associated with hypoxia, ischemia, trauma and exces-
sive neuronal firing elicits large increases in the concentration of ATP and adenosine, 
which has an important role in controlling subsequent tissue damage. Although the ac-
tions of extracellular adenosine are mainly protective, it is an “imperfect endogenous 
  
neuroprotective agent” because, in same scenarios, adenosine receptor stimulation fur-
ther aggravates damage (Picano and Abbracchio, 2000). 
Anyhow, the up-regulation of both adenosine A1 and A2B receptors has been showed to 
play an important role in the protective effects of short cerebral ischemic precondition-
ing in hippocampus; in particular for A1R the increase occurred in neurons while for 
A2BR in astrocytes (Zhou et al., 2004). In the same way, the activation of both A1 and 
A2B receptors seems required for the ischemic preconditioning protection in the heart, 
during early minutes of reperfusion (Solenkova et al., 2006). 
Furthermore, it has been recently suggested a mechanism whereby astrocytes can sense 
the severity of damage in the CNS via ATP release from damaged cells and can modu-
late the TNF-α mediated inflammatory response depending on the extracellular ATP 
concentration and corresponding type of astrocyte ATP/P2 receptor activated (Kucher 
and Neary, 2005). 
The interactions and the reciprocal regulation between P1 and P2 purinergic receptors, 
which also interact as well with cytokines, both in physiological and pathological condi-
tions, are a clear example of increasing biological complexity. It is no chance that P2 
receptor system has been proposed as a “combinatorial receptor web”: the dynamic ar-
chitecture demonstrates economic efficiency and involves a process of “fine-tuning”, a 
mechanism which endorses the dynamic nature of all biological reactions (Volontè et 
al., 2006).  
At the present it is becoming clear that, in biological systems, what matters most is not 
only the single response to a single mediator but above all the final effect of the interac-
tion and the reciprocal regulation between different receptor systems and signalling 
pathways. 
Despite intensive efforts, relatively few adenosine and purinergic receptor ligands have 
made into clinical trials; in fact it is only now that the full potential for drug develop-
ment is becoming clear (Fredholm et al., 2001). Thus, adenosine receptors are and re-
main an attractive target for drug development. 
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